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Voelker, Troy M. Ph. D., February 2000 Chemistry
Synthesis o f Ao-Polydiacetylenic Precursor’s 
and
The Study o f Asymmetric Addition o f Dimethyl Thiophosphite to Imines 
Director: Charles M. Thompson
This research has been divided into two subjects. The first was comprised o f the study 
o f vinyl triflates and terminal acetylenes used as precursors for Ao-polydiacetylenic 
precursors. The second study was to assess the asymmetric addition o f dimethyl 
thiophosphite to imines with chiral auxiliaries.
In the first study, palladium catalyzed cross-coupling o f a terminal acetylene and vinyl 
triflate, which produced a dimer that could be converted into either a terminal acetylene 
or vinyl triflate was accomplished. The dimer was then converted into a terminal 
acetylene and coupled with the vinyl triflate monomer to produce a trimer that allowed 
linear chain growth. The sequence was repeated until the tetramer was produced 
establishing the possibility for Ao-polydiacetylenic precursors to be made by the 
established method.
In the second study dimethyl thiophosphite was added across im ines made from chiral 
amines and aldehydes. The diastereomer ratio ranged from poor (10:9) to good (11:2) 
and was independent o f hydrogen bonding auxiliaries. Separation o f  diastereomers was 
accomplished with some o f the compounds using silica chromatography. The 
asymmetric dealkylation using potassium ethyl xanthate was studied and found to be 
successful on the compounds that did not possess a hydroxy functional group on the 
chiral amine.
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Chapter 1
Introduction
A. Molecular materials
For more than a century, synthetic chemists have demonstrated their ability to 
construct molecules and materials capable o f  fulfilling a huge variety o f  requirements in 
terms o f mechanical, physical, and chemical properties. The electronic properties of 
linear n-conjugated systems (LCSs) have been the subject o f growing importance in 
many areas o f  m odem  chemistry and also in the physics o f  condensed m a t t e r . A t  the 
molecular level, LCSs represent the simplest models o f molecular wires, which together 
with their complementary functions such as molecular switches, or logical gates, have 
contributed to the emergence o f the concept o f molecular electronics.[3] LCSs constitute 
the elemental bricks o f  molecular materials that have given rise to considerable research 
effort in basic and applied material science with the view to develop new materials and 
technological advancem ents.^
Until recently, conjugated polymers (C P’s) represented the best known prototypes 
of LCSs. The unique properties o f CP’s originate from their extended n-conjugated 
system delocalized over a large number o f  recurrent monomer units. The basic model o f 
this class o f materials consists o f alternate single and double carbon-carbon bonds. A 
compound is in conjugation when two or more double bonds are separated by alternating 
single bonds as in 1,3-butadiene. The n systems o f the two conjugated double bonds are 
delocalized over the four carbons and electron flow may be possible.
1
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In plastics, such as polyacetylene, the conjugation extends along the complete 
backbone o f the polym er and has been used to install electronic properties in materials 
that would normally be considered insulators. In becoming electrically conductive, a 
polymer has to imitate a metal, that is, the electrons needs to be free to move and not 
localized to individual atoms. The first condition for this is that the polym er consists o f 
conjugated double bonds. However, it is not enough to have conjugated double bonds.
To become electrically conductive, the polymer has to be disturbed - either by removing 
electrons from (oxidation), or inserting them into (reduction) the material. The process is 
known as doping.
When describing polymer molecules, a  bonds and n  bonds are distinguished by 
their individual properties. The % bonds are fixed, immobile, and form the covalent bonds 
between the carbon atoms. The n electrons in a conjugated double bond system are also 
relatively localized, though not as strongly bound as the a  electrons. Before an electrical 
current can flow along the molecule, one or more electrons have to be removed or 
inserted. I f  an electrical field is then applied, the electrons constituting the n  bonds can 
move rapidly along the molecule chain. The conductivity o f  the polym er chains will be 
limited by the fact that the electrons have to "jump" from one molecule to the next.
Hence, the chains have to be well-packed in ordered rows for conducting to occur.
2
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As mentioned earlier, there are two types o f doping, oxidative or reductive. In the 
case of polyacetylene, the oxidation or reduction reaction equations are written as 
follows:
Oxidation with halogen (p-doping): [CH]n + I2 --------► [CH]nx+ + x I3
Reduction with alkali metal (^-doping): [CH]n + x N a  ► [CH]nx~ + x Na+
The doped polym er is a salt. However, it is not the iodide or sodium ions that 
move to create the current, but the electrons from the conjugated double bonds. 
Furthermore, if  a strong enough electrical field is applied, the iodide and sodium ions can 
move either towards or away from the polymer. This means that the direction o f the 
doping reaction can be controlled and the conductive polymer can easily be switched on 
or off. Applications o f  such materials have been used in the production o f photodiodes, 
flat television screens based on light-emitting diodes (LED), and luminous traffic signs.
The game illustrated in Fig. 1.1 offers a simple model o f a doped polymer. The 
pieces cannot move unless there is at least one empty "hole". In the polymer each piece 
is an electron that jum ps to a hole vacated by another one. This creates a movement along 
the molecule or an electric current.
H H H
w h e re  [ C H J
H H H
3
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Figure 1.1. A game that illustrates polymer doping. In order to align 
the numbers o f the puzzle a piece must be moved into the hole 
creating a new hole which then allows another piece to be moved.
B. Aromaticity
Another principle in chemistry that is a direct result o f a conjugated bond system 
is aromaticity. The most common aromatic compound is benzene. Benzene has the 
molecular formula CefU and is cyclic compound with three double bonds that are in 
conjugation, and therefore, the tc electrons are delocalized around the entire ring. Unlike 
other alkenes, when benzene undergoes electrophilic addition it is quickly followed by 
elimination to restore the stable aromaticity, suggesting that this class o f compounds 
should be treated different then other alkenes. In 1926, a British chemist named Sir 
Robert Robinson, recognized that the compounds that had been classified as aromatic 
always had six electrons, in either n or nonbonding orbitals, in a planar ring. Robinson 
suggested that there was a special stability associated with what he called an aromatic
4
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i
Energy
delocalized n orbitals r
4 — f— 4 — f f — f—
6 degenerate p orbitals
overlap
7C
Figure 1.2. Molecular orbital diagram o f benzene.
sextet. As the theory o f molecular bonding developed, it became clear that a sextet was 
indeed a significant number, corresponding to the number o f  electrons that fill the three 
bonding molecular orbitals o f benzene (Fig. 1.2). Fewer electrons would leave unpaired 
electrons in the bonding orbitals and create a species with radical characteristics. 
Additional electrons would have to go in antibonding m olecular orbitals and would create 
an unstable, high-energy species. Benzene has a filled shell o f  molecular orbitals, just as 
an element such as argon has a filled shell o f atomic orbitals.
In 1931, a German chemist named Erich Hiickel demonstrated that there were 
other numbers o f electrons that corresponded to filled shells for smaller or larger rings.
He proposed what is now known as Hiickel’s rule: “any conjugated monocyclic polyene 
that is planar and has 4n + 2 pi electrons (n = 0, 1,2,  etc.) will exhibit the same stability 
that is associated with benzene.”
Benzene is the ideal aromatic compound. The six carbon atoms in the ring are 
sp2- hybridized, so their regular bond angles o f 120E create a perfect hexagon. The
5
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molecule is planar and totally symmetrical. Because all the ring atoms are carbon, no 
differences in polarity are introduced by the presence o f other elements in the ring. The 
electrons are delocalized evenly over the entire ring. Larger rings with conjugated cis 
double bonds cannot be planar because the bond angles required for such geometrical 
figures cannot be achieved. However, trans double bonds are possible for large carbon 
rings. Such a configuration puts hydrogen atoms on the inside o f the ring where they 
occlude each other and prevent the molecule from being planar. Only in rings consisting 
o f 18 or more carbon atoms is this steric hindrance removed from the molecule (Fig. 1.3). 
Although these larger rings, called annulenes, do not have the stability associated with 
benzene they do have some o f the properties associated with aromaticity. Annulenes 
share properties with aromatic compounds and LCSs. These carbon allotropes possess 
complete Tr-conjugated systems that have a limitless boundary o f carbon skeletons.^
Figure 1.3. [18]Annulene
6
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C. Annulenes
A continuing question in the concept o f aromaticity is the effect o f ring size. 
Various theoretical predictions have suggested that in the upper range o f ring size, 
roughly estimated to be anywhere from 18-30 carbons, the special properties associated 
with aromatic rings will disappear and these allotropes will begin to behave like simple 
p o ly e n e s .A lth o u g h  past synthetic work has provided rings o f  this size,[8] the 
conformational mobility o f these simple annulenes made it difficult to evaluate their 
properties in terms o f polyene vs. aromatic character.1̂  The dehydroannulenes, 
containing acetylene-cumulene bonds, are much more structurally rigid and provide a 
more ideal platform for the study o f aromatic properties in large rings. However, 
assessing the question o f polyyne vs. aromatic character in this series is again difficult 
because o f the unknown alkyne-cumulene anisotropy effects along with the unknown 
effect o f  having short fixed bonds in the annulene perim eter.'10̂
The ideal molecules for studying the aromatic conjugation are those that possess 
rigid, planar annulene perimeters in which all o f the annulene bonds are equivalent. 
Sondheimer and coworkers accomplished the first synthesis
o f [iI]annulene 1, which contains a continuous molecular H H
orbital around the ring. Cyclic compound 1 possesses 18 
^-electrons in conjugation and was the first fully 
conjugated monocyclic system known with more than the 
classical sextet.[12] This milestone in both synthetic and
physical organic chemistry provided experimental support j
H
H H
7
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for the Hiickel rule defining aromaticity and provided a spark for the synthesis o f a 
diverse array o f  macrocylic 71-electron perimeters.
D. Oxidative Acetylene Coupling
The synthesis o f fully conjugated macrocyclic systems is prim arily based on 
acetylenic coupling (Fig. 1.4). First discovered by Glaser[l3] in 1869 and later applied by 
Baeyer| l4] to the formation o f near infinite, all carbon chains known as carbyne, the 
reaction never achieved broad application because the isolation o f  explosive copper 
acetylide was required for the coupling reaction. It was not until modifications to the 
Glaser coupling by Englinton and Galbraith115] whom made use o f cupric salts and donor 
solvents such as pyridine, or Flay116J whom discovered the conditions for homocoupling, 
and Cadiot-Chodkiewicz[171 that developed the heterocoupling reaction that acetylene- 
based molecular architecture took hold in synthetic organic chem istry.[I8] Considerable 
synthetic efforts are currently targeting uncommon molecular architectures and 
functionally advanced materials using acetylene coupling methodologies.
8
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Glaser reaction
/ \  2 CuCl /  \  °2
2 <'-------- ')----:.-:z— H --------------- :---------------- {' >------ = — Cu
\  /  NH4 OH. EtOH \  /  NH4 OH. EtOH
Eglinton and Galbraith
. CuOAc
2 R— ^ — H ----------------------R ------= E ------- = = ------R
0
Hay coupling
CuCl-TMEDA (cat.)
2 R— ^ — H + 0.5 Cb --------- :-----------------R— — R
solvent
Cacfiot-Qiodkiewicz heterocoqiling
1) CuCl, NH; OH-HC!s
EtNHi. MeOH. N-> ____ ___  ___
R = =  H
2) R —= — B r, M e O H
Figure 1.4. Acetylenic coupling reaction conditions.
E. Radialene
W ithin the family o f annulene chemistry is a subset called radialenes. Radialenes 
are a series o f all-methylidene-substituted cyloalkanes o f molecular formula CnH n 
(Fig. 1.5) and has been an active field o f chemistry for the past twenty years.'[19J By 
inserting ethynediyl or buta-l,3-diynediyl moieties into the cyclic radialene framework, a 
carbon rich homologous series o f expanded radialenes is obtained with the molecular
9
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C„Hn
Radialene
C3„Hn
Expanded R adialanes 
x = 0, 1 ,2 , ...etc.
Figure 1.5. Radialene and expanded radialenes’s defined by the 
formula CxnH n (x = 1,2, 3).
formula CnH2n and CnH 3n.[201 In contrast to their constitutional isomers with endocyclic, 
linearly conjugated double bonds such as benzene and cyclooctatetraene, radialenes 
possess an uninterrupted cyclic arrangement o f  cross-conjugated n  systems. The first 
radialene synthesis reported was hexaethylidenecyclohexane 2 (Fig 1.6) in 1961.[211 
Radialenes have always been overshadowed by the linearly conjugated polyenes and the 
arenes in preparative and industrial organic chemistry. Yet recent interest in this 
radialenes has increased significantly because new methods o f synthesis make them more 
accessible, and they are potential candidates for the construction o f organic conductors 
and ferromagnets.[22]
The highly symmetrical structure o f radialenes, suggested by their constitutional 
formulas is not only aesthetically appealing but also stimulates the fantasy o f the chemist.
10
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It is thus not surprising that the search for a fitting trivial name for these regular 
structures with the double bonds “radiating” from the central ring led to the name 
“radialene”.1221 Although this term was coined originally for the 
hexamethylenecyclohexane 2, it was quickly adopted for the whole series. To 
differentiate between its various members, a nomenclature was adopted in which the 
number o f the exocyclic double bonds was put in parentheses in front o f  the word 
radialene, e.g., [231radialene (n = 3, 4 ,..).
650° C
10"3 Ton- 10'1 Torr ,CI
Figure 1.6. Two thermalytic routes to radialene (2).
Methods o f  preparing radialenes fall into two general synthetic strategies: (1) 
olefm-forming reactions at an already existing cycloalkane skeleton, and (2) thermal, 
photolytic, or metal-induced cylooligomerization reactions o f suitable1231 cumulenes (Fig. 
1.6). The latter method has turned out to be the more versatile and successful one so far, 
although it still cannot compete in product selectivity with the former.
Diederich and Boldi[24] were the first to synthesize a series o f expanded radialenes 3-5 
(Fig. 1.7). The most direct synthetic route to these compounds would be by means o f an 
Eglinton-Glaser cyclization o f tetraethynylethene 6. Unfortunately, this method did 
not afford any isolable quantities o f the macrocyles but instead led to oligomeric 
material.[24] To favour cyclization and provide 3-5 over competing polymerization
11
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R R
R R
R R
5
R = TIPS (triisopropylsilyl; iPr3Si-)
Figure 1.7. Perethynylated expanded radialenes synthesized by 
Diederich and Boldi.19
reactions, the authors had to access the radialenes by first making the dimeric compound 
9 (Scheme. 1.1). The dimer was prepared by sequential, kinetically controlled 
deprotection o f trimethylsilyl (TMS) and triethylsilyl (TES) in the presence o f the 
analogous triisopropylsilyl (TIPS) protected groups o f compound 7. After removal o f the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
•TIPS
R 1 R2 R3
6 TIPS H H
7 TIPS TES TMS
8 TIPS TES H
TIPS
CuOAcCuOAc ► 3 + 5
(15%) (20%)
9: R = TES 
10: R = H
•TIPS •TIPS
TIPS. •TIPSTIPS. •TIPS
CuOAc
TIPS TIPS
10 + 12 CuOAc
N
11: R = TES 
12: R = H
4
(15%)
Schem e 1.1. Synthesis o f perenthynylated radialenes.
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TMS group, 8 was homocoupled under Eglinton-Galbraith conditions to afford dimer 9. 
Removal o f the TES protecting group to afford 10 and a second homocoupling, produced 
3 and 5 in 15% and 20% yield.
In order to prepare the pentagon radialene 4, the trimer 11 had to first be produced 
via a heterocoupling between 6 and 8. After removal o f the TES protecting group an 
oxidative cyclization between 12 and 10 produced 4 (15%) as the major product with a 
small amount o f  3 and 5 from the respective homocoupling reaction. All three radialenes 
are readily soluble, highly stable compounds with melting points above 260EC. The 
stability o f the radialenes indicates the absence o f free terminal alkyne groups which 
generally destabilize polyacetylenic n  systems.
The particularly high stability o f 3-5 may well be due to inefficient cross­
conjugation, which cannot compete with linear 7i-electron conjugation in these 
systems.[25] Inefficient cross-conjugation could be a general stabilizing principle of 
unsaturated carbon-based matter: fullerene C6o is best described as a cross-conjugated 
molecule with radialene[23J substructures and graphite may also be viewed as cross­
conjugated. The high solubility o f 3-5 probably is more due to the presence o f  the TIPS 
groups rather than cross conjugation but this phenomenon still leaves hope for the 
construction o f larger molecules with similar properties.
Although the production o f expanded radialenes is remarkable in itself there are 
some drawbacks to the syntheses. It is four steps to prepare the tetraethynylethene 6 and 
although the protecting groups are a product o f the coupling reaction to make 6 the 
subsequent selective, kinetically controlled deprotection to afford the dimer 9 and trimer 
10 resulted in overall low yields and significant losses o f  material from over deprotection. 
An important facet to radialene synthesis that arose from these experiments is the
14
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methodology o f a stepwise synthesis o f polymeric molecular rods. Although the direct 
synthesis from a single monomer unit is possible the by-products from such a reaction 
obviates any type o f purification.
F. Iterative Radialene Synthesis
The challenge exists to develop supramolecular chemistry into a more systematic 
science, and therefore, methods need to be available for encoding molecular building 
blocks in a way that is simple, yet offers total specifity.[26] In order to mimic the best- 
known natural supramolecular systems such as the nucleic acids and proteins, synthetic 
methods that allow efficient, but versatile construction o f  complex molecular objects 
from simple building blocks are desirable. Dissections o f structures 3-5 indicate that the 
major drawback to the syntheses is not the low yielding oxidative coupling but rather the 
inefficient choice o f tetraethynylethene as the monomer unit. The numerous steps to 
produce tetraethynylethene is simply too extensive to make production o f the 
macrocycles on a large scale impossible. So there is an obvious need for further 
development o f acetylenic building blocks that are easy to prepare and functionalize.
The stepwise construction o f networks, in other words the transformation o f 
appropriate monomers into successively larger oligomers, is the most promising 
approach. In this approach the solubility o f the larger system can be estimated from the 
properties o f the smaller molecules. If necessary the monomers can be modified to 
improve the desired properties o f  the anticipated network. Any repetitive methodology 
for assembling covalently linked sequences o f monomeric units must be able to control 
chain length, sequence order o f monomers, and end-group functionality. In addition, the
15
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
method must be efficient and versatile. The solid-phase methods pioneered by 
M e rrif ie ld ^  remain the methods o f  choice o f  complex polypeptides, especially when 
each successive unit is different from the previous. However, it is clear that this 
approach is not easily adapted to other complex molecular systems.
Coupling
ApBj d ep rotection
Ap-{BA)-B___
/  V -  B
i  J—
-A-(BA)-B-
Figure 1.8. Iterative cycle to synthesis o f radialene precursors. 22
For sequences that are periodic or sequences that have extensive periodic 
segments, the repetitive method established by M o o re ^  (Fig 1.8) is considerably more 
efficient as long as you can avoid solubility and purification problems. The cycle begins 
by selective deprotection at each o f the two ends o f the diprotected m onom er APBP, 
yielding the monoprotected intermediates APB and ABP. These are often coupled to give 
the dimer A pBABp protected in the same manner as the monomer unit. The process can 
be repeated n times to give a sequence o f length 2". Sequences o f length other than 2", as 
well as sequences having particular arrangement o f co-monomer units, can be realized by 
merging parallel repetitive cycles. For example, a hexamer sequence is achieved by 
combining tetramer and dimer sequences.
16
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A common feature in the preparation o f carbon-rich systems is the use o f the C-C 
triple bond as a functional group and linking unit. The alkyne group is the only easily 
preparable all-carbon building block; terminal alkyne functions can be linked to sp2-C-X 
( X = halogen) molecules readily and in high yields with certain oxidative coupling 
procedures. Thus, the acetylene function is indispensable not only in the construction o f 
carbon-rich structures but also in the synthesis o f  larger rings. The relative rigidity and 
linearity o f  the acetylene fragment is a further advantage in the synthesis o f rigid and 
uniformly shaped structures. So if  the acetylene functional group can not be removed 
from the methodology o f  the synthesis then the vinyl coupling unit is the only functional 
group left to be explored.
A typical synthesis is illustrated by the palladium-catalyzed cross coupling1291 o f 
monomers TM S!A!Br and H!B!N=N!NEt2 which has trimethylsilyacetylene and 1-aryl- 
3,3-diethyltriazene end group functionalities (Scheme. 1.2).[261 Reaction o f  TMS1AB! 
N=N!NEt2 with methanol in the presence o f a catalytic amount o f  potassium carbonate 
gives terminal acetylene H!AB!N=N!NEt2 . In contrast, reaction o f  TMS! AB!N=N!NEt2 
with methyl iodide gives aryl iodide TMS!AB!I. Intermediates H!AB!N=N!NEt2 and 
TMS1AB1I are then cross-coupled to give tetramer H! (AB)2N=N!NEt2 which has the 
exact same end group functionalities as dimer
17
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CH,I
TMS
TMS
Pd
TMS
TMS
Pd'
TMS
Schem e 1.2. Controlled synthesis o f phenylacetylene sequences.
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H!AB!N=N!NEt2 . This process can be repeated n times to give a sequence o f  length 2".
A key to the success o f this approach is that trimethylsilylacetylene and 
1-aryl-3,3-diethyltriazene function very effectively as complementary protecting groups 
for terminal acetylene and aryl iodide. Each o f  the two protecting groups can be 
selectively removed in the presence o f the other, and both protecting groups are stable to 
the cross-coupling reaction conditions. After a few iterations o f the sequence well- 
defined phenylacetylene sequences (PAS) can be used to prepare phenylacetylene 
macrocyles (PAM). Deprotection o f both masking groups from the sequence’s termini 
give difunctional intermediates such as H-(AB)6-I. Upon intramolecular cyclization o f 
PAS’s rigid macrocycles are obtained with larger internal diameters in high yield under 
optimized cyclization conditions. Although the synthesis does not provide a route to 
radialene compounds it does define the methodology employed by most in the radialene 
research community.
While studying triflate derivatives, Stang^30̂ prepared compound 13, which was 
singled out as a class o f  molecules ideally suited to probe the electronic characteristics of 
cross-conjugation in organic molecules and provide a monomer unit suitable for radialene 
synthesis. Tykwinski[311 reported the iterative synthesis and characterization o f  this class 
o f oligomers. Palladium-catalyzed coupling o f terminal alkynes with vinyl triflates[32] 
provided an alternative to coupling terminal alkynes to vinyl halides and an efficient 
route to the desired oligomers. Tykwinkski assembled the Ao-polydiacetylene (PDA) 
beginning with a palladium catalyzed cross-coupling o f trimethylsilylacetylene and vinyl 
triflate monomer 13 to afford 14 (Scheme. 1.3). Protodesilylation o f 14 gave the 
deprotected diyne that could then be coupled with 13 to afford trimer 16. Using 16, 
iteration o f the protodesilylation and coupling sequence gave pentamer 18. The assembly
19
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of radialene 21 required protodesilylation o f 18 followed by cross coupling with 
dibromoolefm 20. Although dilute reaction conditions was necessary to delineate the 
formation o f linear oligomers the cyclization reaction did require seven days for 
completion. W ork up and column chromatography gave the pure macrocycle in modest 
yields due to decomposition during purification.
TMS
13 k 2c o 3
14: R = TMS 
15: R = H
Br Br
3 R
19: R = TMS 20 
20: R = H
+ X
K2C 0 3
16: R = TMS 
17: R = H
K2C 0 3 C X
21
Schem e 1.3. Iterative synthesis o f Ao-PDA’s.
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The work done by Tykwinski proved that 13 is an effective and efficient building 
block for the production o f iso-PDA’s and radialenes. The synthesis does have a limit in 
terms of radialene synthesis due to the fact that chain elongation takes place on both ends 
o f the Ao-PDA. Plus, this type o f approach does not allow for chain growth to proceed in 
a geometric fashion due to only the monomer unit being used for chain elongation rather 
then being able to couple a dimer to a dimer, or a trimer to a dimer, etc.
G. Statement of the Problem
Expanded radialenes, molecular wires, and polymers with polyacetylenic, 
conjugated backbones are compounds o f extended C-cores and are materials with unusual 
structural and electronic properties. Macrocylic ring systems containing multiple 
acetylenic units m ay have possible ligand binding properties or provide a core for the 
construction o f expanded dendrimers. Rigid acetylenic molecular rods o f  defined length 
can serve as precursors to molecular wires for potential electronic devices. The 
preparation o f acetylenic precursors for the construction o f such molecules has been an 
interest in synthetic chemistry in the past decade. The goal of this project is to develop a 
novel synthetic route to the construction o f polyacetylenic backbone precursors based on 
palladium cross-coupling reactions between vinyl triflates and terminal acetylenes.
It was in the interest o f this investigator to study the possibility o f using 13 in an 
iterative synthesis that would adapt to M oore’s methodology. By using 22, the precursor 
to 13 and readily accessed from bzs-trimethylsilyl acetylene and the acid chloride, an iso- 
PDA  with geometric growth may be realized (Scheme 1.4). By using the ketone and the 
trimethylsilyl group o f  22, a set o f complimentary protecting groups for the coupling
21
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reaction is realized. Specifically, if  22 were converted to triflate from the ketone, and 
then cross-couple the triflate with the terminal acetylene acquired from desilylation of 22, 
a dimer would be produced that has the same protection scheme as the monomer.
Through the iterative process established by Moore, an iso-PDA could be produced with 
the same 2" chain growth. Once the iso-PDA has reached the length desired for the 
macrocycle both ends o f the chain are then deprotected and fused to make the radialene.
22
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Scheme 1.4. Proposed synthetic design for Ao-PDA’s.
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Chapter 2
Synthesis 
A. Iso-PDA framework
An iterative method o f chain elongation was used to assemble the cross­
conjugated precursors to the radialenes by utilizing palladium-catalyzed cross-coupling 
o f terminal acetylenes and vinyl triflates. The coupling sequence is sufficiently mild 
enough to tolerate the unsaturated iso-PDA framework o f the precursors, including the 
protecting groups masking the active coupling units, and allows modular incorporation of 
the different substituents required to maintain solubility or vary electronic effects.
The monomer unit 22 is made from the reaction o f  6A-(trimethylsilyl)acetylene 
with isopropyl acyl halide under Friedel-Crafts conditions (Scheme 2.1). Isopropyl acyl 
chloride was chosen as the acid chloride because once it is converted to the 
isopropylidene it could be distinguished by its singlet in the ^  NM R, making spectral 
analysis less complex on the radialene product. The reaction is conceived as an 
electrophilic displacement o f  one trimethylsilyl moiety by an acyl group which proceeds 
cleanly because o f  the electron-withdrawing power o f  the acyl substituent deactivates the 
ethynyl-silicon bond o f the product toward further attack.[33J The acyl group which 
inhibits the breaking o f the ethynyl-silicon bond under Friedel-Crafts conditions enhances 
the reactivity o f  the trimethylsily group toward nucleophilic displacement and can be 
cleaved by weak base. The TMS group o f 22 was selectively cleaved with a 1:8 solution 
o f 0.01M borax(aq) in methanol in 36 h at rt but was found to be too volatile for the 
synthetic scheme. So to add some bulk to the monomer unit and some diversity to the
24
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o
TMS-
R Cl
O
R'
TMS
22: R = CH(CH3 ) 2  
31: R =  cyclohexyl
-TMS
A1C1
TMS
Tf2 0 ,
22: R = CH(CH3)2; 62% 
31: R = cyclohexyl; 89%
OTf
CHnCl
R ^
^"'T M S
32: R = CH(CH3)2; 78%
33: R = cyclohexyl; 74%
O
0.01 M borax
MeOH
34; 87%
OTf
+
TMS
32
TMS
35
Schem e 2.1. Synthesis o f monomer coupling compounds (vinyl 
triflate and terminal acetylene).
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'H NMR spectrum, cyclohexyl acid chloride was used as a co-monomer in the production 
o f the radialene precursors. Gas chromatography (GC) was used to track the progress of 
the desilation reaction by monitoring the decrease in area o f  the l-cyclohexyl-3- 
trimethylsilanyl-propynone peak (Rt = 8.40 min) and the rise o f the 1-cyclohexyl 
propynone, 31 , peak (Rt = 6.44 min).
Standard conditions for making the triflate[34] were attempted, but all afforded, 
along with left over starting material, tarring and very low yields, or no desired product. 
The triflates 32 and 33 were eventually prepared by the reaction o f the corresponding 
ketone with the bulky base 2,6-di-t-butyl-4-methylpyridine and triflic anhydride in 
CH2CI2 in 78% and 74% yield.1̂  Use o f the non-nucleophilic, sterically hindered 2,6-di- 
t-butyl-4-methylpyridine rather then standard bases was essential in this step.
Triethyl amine, pyridine, and collidine result in heterogenous reaction conditions as the 
anhydride reacts with these nucleophiles affording amine salts that precipitate out o f 
solution. The sterically hindered base 2,6-di-i-butyl-4-methylpyridine acts as a true 
Lewis base and is incapable o f reacting with the anhydride which allows the carbonyl 
oxygen to attack the anhydride and increases the rate o f the reaction.[30] After 
nucleophilic attack by the carbonyl oxygen 2,6-di-t-butyl-4-methylpyridine scavenges the 
proton form the a  carbon and forms a salt. The amine salt formed in the triflate reaction 
can be collected and the 2,6-di-t-butyl-4-methylpyridine base can be recycled if  desired 
for future reactions. A GC was used to monitor both o f the triflate reactions and the 
structures o f 32 and 33 were confirmed by the triflouromethyl quartet in the l3C spectrum 
(Fig. 2.1).
26
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J =  320,4 Hz
CF
TMS
13Figure 2.1. C NM R spectrum o f the isopropyl vinyl triflate 
showing the quartet o f-C F j
C. Heck Coupling
Cross-coupling o f 32 and 34 under standard Heck conditions did not afford the 
desired product 35 (Scheme 2.1), but rather an insoluble thick black tar and recovered 
vinyl triflate. The initial thought was that the enol tautomer of the ketone was forming 
under the basic conditions o f the cross-coupling reaction and thus consuming the terminal 
acetylene starting material. Since the carbonyl group is essential to make the vinyl 
triflate a protection scheme was devised in order to stop the enol formation (Scheme 2.2).
27
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
o
+ TfOTMS
FT TMSO OTMS CH2C12 -78 °C
'TMS
22: R = C(CH3)2
31: R =  cyclohexyl
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TMS
36: R = C(CH3)2; 87%
37: R = cyclohexyl; 68%
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Ck .0 k 2c o 3 C\ .0
TMS
36 38; 87%
OTf Pd(PPh3)4
Cul
TEA
TMS
39; 23%
Scheme 2.2. Protection of the a,p-unsaturated ketone and 
palladium cross-coupling.
Since the protecting group would have to be stable to the basic reaction conditions 
used in the desilation and cross-coupling reactions the 1,3-dioxolane moiety was the most 
attractive choice. Several attempts at ketalization o f 22 with typical m ethods[35] using 
ethylene glycol in the presence o f various catalysts, such as pyridinium p- 
toluenesulfonate, p-toluenesulfonic acid, or Amberlyst 15 ion exchange resin, resulted in
28
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either no product or a complex mixture o f products as indicated by NMR, GC, and TLC 
analysis. The most successful standard procedure was the use o f 
2,2-dimethylpropanediol andp-TsO H  refluxed in benzene for 48 hrs which still only 
produced a 45% yield o f  the ketal.
To avoid such forcing conditions, a more facile approach was needed. Noyori 
reported an efficient ketalization procedure involving bN-trimethylsilylethylene glycol 
(BTSE) and M e3SiO Tf as reagents on a,P-unsaturated ketals.[36] The idea is to shift the 
equilibrium o f the reaction toward the products by forming the very stable 
hexamethyldisiloxane. The isopropyl monomer 22 was chosen to make the ketal because 
the 'id peaks o f the methyl groups could be easily distinguished from the ketal protons. 
The Noyori reaction conditions were conducted on 22, the progress monitored by GC, 
and the isolated product had the expected 'H  spectrum for the ketal group (Fig. 2.2). The 
yield was vastly improved (87%) and 36 became available for further study
Once the ketal was installed desilation could be done under more basic conditions 
without the loss o f  starting material or possible Michael additions. The use o f K 2CO3 
decreased the time o f  this step from 36 to 3 h. Palladium catalyzed cross-coupling o f 
33 and 38 under standard Heck conditions led to the formation o f 39 (Scheme 2.2). But 
all attempts to remove the ketal protecting group from 39 led to little or no product 40. It 
became obvious that the direct coupling o f 32 and 34 should be explored under a variety 
o f conditions in order to avoid a large loss o f material to protection and deprotection.
29
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TMS
Figure 2.2. 'H  NMR o f 2-m ethyl-3-[l,3]dixolane-l-trim ethylsilyl-l- 
pentyne showing the ketal protons.
In order to explore different conditions for the Heck reaction it was prudent to 
examine the mechanism o f the cross-coupling reaction (Fig. 2.3). The first step o f the 
catalytic cycle is the oxidative addition aryl halide to the putative 14-electron complex 
Pd0(PPh3)2 to afford a cj-arylpalladium (II) complex. The second step is a nucleophilic 
attack on tra«5-ArPdX(PPh3)2 with a sy«-addition o f  the olefm. The final product is 
generated by a p-hydride elimination via a base. Cross-coupling reactions are catalyzed 
by Pd°(PPh3)4 , but it has been established that Pd0(PPh3)2, which forms after two
30
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Pd°(PPh3)4
ArX
oxidative additionNEt
Ar
syn addition
'-hydride elimination
H R
Figure 2.3. Pd° catalyzed cross-coupling reaction mechanism.
decomplexations o f  PPI13 is the transient reactive species in the oxidative addition o f 
ArX. However, its concentration is extremely low because it is involved in an 
endergonic reaction with the major but unreactive species Pd0(PPh3)3 . The result o f the 
equilibrium is a low turnover rate in the cross-coupling cycle which in turn means longer 
reactions times and loss o f the terminal acetylene due to base instability. Reducible 
palladium (II) complexes such as PduCl2(PPh3)2 was considered a possible better 
precursor since their reduction in situ was expected to yield quantitatively the reactive 
Pd0(PPh3)2 complex, but the need for a strong base again negated this route. Since the
31
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problem o f the reaction seemed to be with the base, a study was done testing the stability 
o f 34 with a variety o f  bases.
By simply placing a small aliquot o f 34 in some test tubes with benzene followed 
by the addition o f an amine base and monitoring by GC and color the decomposition of 
34 could be followed by the reduction in peak 6.44 min and the rise o f several peaks that 
were never analyzed. The three bases that had little or no reaction with 34 were the bulky 
base 2,6-di-f-butyl-4-methylpyridine, 2,6-di-f-butylpiperidine, and H unig’s base.
Although all three bases still resulted in decomposition o f 34 it was a slow degradation. 
All the bases were tried in the cross-coupling reaction and only H unig’s base gave 
satisfactory results. 2,6-Di-f-butyl-4-methylpyridine and 2,6-di-f-butylpiperidine reaction 
times were long requiring several days and up to 10 eq. o f  34 in order for full 
consumption o f vinyl triflate 32. The reaction with Hunig’s base was complete in 48 h 
and only used 5 eq. o f 34 to complete the reaction. With the cross-coupling reaction 
conditions established, 35 was made successfully via coupling o f 32 to 34 (Scheme 2.3). 
The reaction was monitored by GC with the decrease o f the starting material peaks (32,
Rt = 7.1 min; 32, Rt = 6.4 min) and the growth o f a new peak (Rt = 11.2 min). 'H  NMR 
analysis confirmed product 35 with the ]H NM R spectra showing both the methyl 
singlets from 32 and the TMS singlet from 34 (Fig. 2.4, 2.5).
32
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Figure 2.4. ]H NMR spectra o f l-Cyclohexyl-4-isopropylidene-6-trimethylsilyl- 
2,5-hexyne-l-one 35.
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Figure 2.5. A; ,3C NMR full spectra o f l-Cyclohexyl-4-isopropylidene-6- 
trimethylsilyl-2,5-hexyne-l-one 35. B; 220-90 ppm. C; 60 -  (-)10 ppm.
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Scheme 2.3. Heck coupling with Hunig’s base, attempt at the production of 
the dimer vinyl triflate, and route to the dimer terminal acetylene.
With dimer 35 made successfully, the next iteration step required the preparation vinyl 
triflate 41 and terminal acetylene 42 (Fig. 2.6). The terminal acetylene was prepared 
successfully using the same conditions (0.1 M borax(aq)) used to make the monomer unit. 
The vinyl triflate dimer 36 was detected by 13C NMR but was unstable to silica gel and 
proved to be difficult to purify. Other methods o f purification were tried; alumina gel led 
to the same decomposition as silica, vacuum distillation never resulted in any product, the 
oil was simply to unsuitable for recrystallization, and even freezing the product in a 
benzene matrix still resulted in a black tar. Using crude 35 in the Heck coupling reaction
35
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Figure 2.6. A; *H NMR and B ;UC NMR o f the dimer terminal acetylene.
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was tried but either the vinyl triflate decomposed during the reaction or byproducts 
poisoned the palladium catalyst. In an effort to save product and time a new scheme was 
put in place that would make the z'so-PDA radialene precursor via coupling a monomer 
unit to the chain at each step (Scheme 2.4). The new approach would still allow many 
different m onom er units to be incorporated into the Ao-PDA but would require extra 
steps to achieve the desired chain length.
Pd(PPh3)4
OTf
42
TMS
Cul TMS
33 43; 59%
43
0.01 M B orax; 
MeOH
OTf
44 +
44; 84%
Pd(PPh3)4 
I Cul
TMS
TMS
32
45; 36%
Scheme 2.4. Chain elongation via monomer coupling.
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The heterocoupling o f  42 and 33 led to the successful production o f  the triraer 43. 
The compounds had too high o f a boiling point to be monitored by GC so all o f the 
remaining reactions were analyzed by TLC. A silica column with EtOAc/hex (1 :99) 
eluted pure 43 as light yellow oil and was verified by ‘H and l3C NMR (Fig. 2.7, 2.8). 
Desilation o f 43 was accomplished with 0.1 M borax to afford 44, but its purification was 
never fully elucidated due to the similar Rf values o f  both 43 and 44 creating an overlap 
with the two compounds in the NMR spectra. Since, 43 would be fairly inert to the 
conditions o f coupling 44 with 32, it was used impure and did successfully produce 40, 
although in modest yield. A silica column with EtOAc/hex (0.5:99.5) eluted pure 45 as 
dark yellow oil, that quickly turned dark red if  left at rt and was verified by 'H  and ,3C 
NMR (Fig. 2.9,2.10).
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Figure 2.7. ]H spectra o f  l-Cyclohexyl-7-cyclohexylidene-4-isopropylidene-9- 
trimethylsilanyl-nona-2,5,8-triyn-l-one (43).
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Figure 2.8. I3C spectra o f l-Cyclohexyl-7-cyclohexylidene-4- 
isopropylidene-9-trimethylsilanyl-nona-2,5,8-triyn-l-one (43).
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Figure 2.9. H spectra o f 1-cyclohexyl-7-cyclohexylidene-4,10-isopropylidene- 
12-trimethylsilanyl-2,5,8,l 1-dodecyn-l-one (45).
41
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
H-t
f
TMS
Figure 2.10. I3C spectra o f l-Cyclohexyl-7-cyclohexylidene-4,10- 
isopropylidene-12-trim ethylsilanyl-2,5,8,ll-dodecyn-l-one (45).
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Chapter 3
Conclusions and Future Work
A. New Radialene Scheme
The use o f  acyl chlorides and bis-(trimethylsilyl)acetylene as precursors for iso- 
PDA framework has been a success. Unfortunately, making the vinyl triflate with the 
dimer was unsuccessful and thus chain elongation could only be achieved with the 
monomer units. In order to realize the radialenes from the iso-PDA precursors, a new 
scheme for the production o f a vinyl halide will have to be implemented (Scheme 3.1). 
Pross and Sternhell^7' established a route to vinyl iodides via a hydrazone intermediate. 
The hydrazone is prepared by condensing hydrazine hydrate and the ketone in EtOH. 
Then a solution o f  the hydrazone and TEA is cooled to 0 EC and a saturated solution o f 
iodine and THF is added to yield the vinyl iodide. An intramolecular cross-coupling 
reaction with the terminal acetylene and vinyl iodide would then yield the expanded 
radialene. Once the radialene has been made, a UV-vis spectroscopic analysis will be 
conducted to establish the contribution o f the cross-conjugation to the overall 7t-electron 
delocalization in the ring.
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Scheme 3.1. Future radialene scheme.
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Chapter 4
Introduction
A. Endogenous Vasoactive Peptides
Since their discovery, endogenous vasoactive peptides have attracted considerable 
interest because o f their concerted actions on the heart, vascular smooth muscle and 
kidney, as well as their ability to alter the release o f hormones and neurotransmitters. 
Although much information has been obtained regarding their vasoconstrictor and 
mitogenic actions, their involvement in modulating the activity o f the cardiovascular 
system under normal conditions has not been fully elucidated. A better understanding of 
their role in pathogenesis o f a variety of diseases such as hypertension, artherosclerosis or 
active renal failure is required.[38J The endogenous vasoactive peptides presumably act 
through a variety o f mechanisms to control vascular tone and peripheral blood flow J3̂  
Some o f these peptides (angiotensin II, vasopressin, and neuropeptide Y) are potent 
vasoconstrictors while others (atrial natriutetic peptide and bradykinin) are vasodilators 
acting in parallel to maintain homeostasis.f40J These peptides are known to be released 
mostly by endothelial cells to mediate vasoconstriction in response to various chemical 
and physical s t im u li .^  Since the initial description o f angiotensin II-mediated 
hypertension some 40 years ago, basic and clinical investigations o f the renin-angiotensin 
system (RAS) have resulted in broader understanding o f cardiovascular pathophysiology 
and significant advances in therapy. Angiotensin-converting enzyme [42] inhibitors
45
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Figure 4.1. Pathophysiology o f the RAS. SMC indicates smooth muscle cell 
(scheme from Givertz et al. 2000).
and angiotensin receptor antagonists are now widely prescribed for the treatment o f 
hypertension and left ventricular dysfunction^431
Renin is released by juxluloglomerular cells in the kidney in response to renal 
hypoperfusion, decreased sodium delivery, and sympathetic activation (Fig. 4.1). 
Angiotensinogen produced by the liver is cleaved by renin, through the hydrolysis o f a 
Leu-Val bond, to yield the inactive N-terminal decapeptide angiotensin I. Circulating 
angiotensin I is in turn, converted to angiotensin II in the lungs by the action o f ACE, 
which cleaves a two amino acid fragment from the C-terminus end o f angiotensin I.|44) 
ACE, or kininase II, also plays a key role in the kallikrein-kinin system by cleaving 
bradykinin to inactive peptides. In addition to the hormonal effects o f circulating
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angiotensin II, all o f the necessary components o f the RAS exist in several organs and 
tissues, including the heart, kidneys, and vasculature.1451
Angiotensin II exerts its actions in target organs and tissues by binding to both 
angiotensin II type 1 and 2 (ATi and AT2) receptors, although adverse effects in humans 
seem to be mediated primarily by the ATi receptor (Fig. 4.2).[46] In the kidney, 
angiotensin II causes sodium and water retention and efferent arteriolar vasoconstriction. 
Constriction o f the systemic vasculature by angiotensin II causes hypertension, whereas
Figure 4.2. Synergistic effects resulting from combined ACE and NEP inhibition 
are due to similar mechanisms, leading to blockade o f angiotensin (AT) synthesis 
and concomitant potentiation o f effects o f natriuretic peptides and bradykinin, 
leading to vasodilatation, natriuresis, and improvement in myocardial function. ET-1 
indicates endothelin; ECE, endothelin-converting enzyme; AT, angiotensin; Thr, 
thrombin; Bk, bradykinin; pGC, particulate guanylate cyclase; and sGC, soluble 
guanylate cyclase (Scheme from Zhang et al. 1998).
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coronary vasoconstriction may cause myocardial ischemia and arrhythm ias.1471 
Angiotensin II-stimulated secretion o f aldosterone by the adrenal cortex and arginine 
vasopressin by the posterior pituitary contributes to extra cellular volume expansion and 
sympathetic activation. 1481 O f particular relevance to the progression o f  cardiovascular 
disease is the recognition that angiotensin II and aldosterone exert pleiotropic effects in 
the heart and systemic vasculature that result in myocardial and vascular remodeling.1451 
Important biological events include cellular hypertrophy, interstitial fibrosis, apoptosis, 
inflammation, and thrombosis. Increasing evidence points to the RAS as a major 
contributor to the progression o f atherosclerosis.1491
The key factor in the production o f  angi otensin II is the enzyme ACE, and thus is 
a major target for therapy in cardiovascular disease. ACE, a glycoprotein widely 
distributed in mammals, is a membrane-bound enzyme localized mainly in endothelial 
cells with an expression level higher in atria than in ventricles.1501 ACE is also a well 
known zinc-containing carboxypeptidase’s that has a central role in blood pressure 
homeostasis. 1511 ACE transforms angiotensin I into angiotensin II and degrades 
bradykinin, a potent stimulator o f the L-arginine and cyclooxygenase pathways.1521 
Therefore, inhibitors o f ACE not only prevent the formation o f a potent vasoconstrictor 
with proliferate properties but also increase local concentrations o f  bradykinin and, in 
turn, the production o f NO and prostacyclin.1531 The latter may participate in the vascular 
protective effects o f  ACE inhibitors by improving blood flow and preventing platelet 
activation.
In clinical studies, ACE inhibitors decreased systemic vascular resistance without 
an increased heart rate and promoted natriuresis.1541 The favorable effect o f  ACE 
inhibition has been documented in many large, randomized trials in hypertension, after
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myocardial infarction, and in congestive heart failure (CHF).1551 M ore recently, ACE 
inhibitors have been shown to decrease clinical events in high-risk patients with 
atherosclerosis with and without ventricular dysfunction and before and after myocardial 
infarction.1561 Moreover, studies have confirmed that ACE inhibitors are vascular- 
protective independent o f their effects on blood pressure and ventricular remodeling.1571
The clinical effects o f ACE inhibitors in the treatment o f hypertension and CHF 
underline the importance o f neurohumoral blockade. Since the introduction o f captopril 
in 1975, many long-acting molecules have been developed.1581 Despite their clinical 
efficacy, however, a substantial number o f hypertensive are not adequately controlled 
with ACE inhibitors and need combination therapy with diuretics, P-blockers, and/or 
calcium antagonists.1591 Furthermore, clinical studies in early stages o f  CHF 
demonstrated that ACE inhibitors are less effective in patients with high levels o f ANP, 
epinephrine, and renin activity.*60* Thus, the development o f new drugs that act on 
neurohumoral systems other than the RAS may be advantageous.
B. Natriuretic Peptides
The family o f natriuretic peptides consist o f three isoforms: atrial natriuretic 
peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).16' 1 
Both ANP and BNP are synthesized in the atrium o f the heart under physiological 
conditions and in the ventricles in the presence o f  ventricular hypertrophy, and CNP in 
endothelial cells.*621 ANP infusion reduces blood pressure while increasing urine volume, 
urinary excretion o f sodium, and inhibits renin and aldosterone secretion,1631 and
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increases the hypotensive effect o f BNP.[64] ANP also inhibits endothelin production and 
proliferation o f  vascular smooth muscle cells and myocardial hypertrophy, and ANP has 
been shown to have significant sympatholytic effects as well.[65] Because o f  its biological 
effect as an antagonist to angiotensin II, ANP is an endogenous inhibitor o f the RAS 
(Table 4.1).'-66̂ ANP and BNP production in myocardium is induced by increased atrial 
pressure, as m ay occur with increased sodium intake and by decreased left ventricular 
function
Table 4.1. Natriuretic Peptides Have Contrasting Biological Effects to 
Angiotensin II.
Angiotensin II Natriuretic Peptides
t Blood pressure 4
4. Renal sodium secretion t
t Aldosterone 4
4- Renin secreti on 4
t Sympathetic nerve activity 4
t Cell proliferation 4
f Hypertrophy 4
Circulating ANP, BNP, and CNP are quickly metabolized and inactivated by the 
specific enzyme neutral endopeptidase (NEP).[6?! The short half-life o f the natri uretic 
peptides, as well as the fact that a peptide is difficult to administer and expensive to 
produce, limits the option o f an exogenous application of the peptide as a possible 
therapeutic strategy. It should be noted that BNP has emerged as an efficacious
50
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intravenous agent for the treatment o f CHF.1671 Therefore, pharmacological inhibition of 
the metabolism o f natriuretic peptides is an attractive alternative therapeutic target.
C. Neutral Endopeptidase (NEP)
NEP is an endothelial, membrane-bound Zn-metallopeptidase similar to ACE 
that cleaves peptides at the amino side o f hydrophilic residues.1681 The membrane-bound 
metalloproteinase has a catalytic unit similar to ACE. NEP is w idely distributed in 
endothelial cells, smooth muscle cells, cardiac myocytes, renal epithelial cells, and 
fibroblasts. NEP is also found in the lung, gut adrenal glands, brain, and heart.1681 It 
catalyzes the degradation o f vasodilator peptides, including ANP, BNP, CNP, and 
bradykinin, as well as vasoconstrictor peptides like angiotensin II.
Selective NEP inhibitors prevent, in vitro and in vivo, the degradation o f 
natriuretic peptides and increase their biological activity.169* In addition to degrading 
vasoactive peptides to inactive products, NEP is also involved in the enzymatic 
conversion o f big endothelin to its active form, the vasoconstrictor peptide endothelin- 
l .1701 Certain NEP inhibitors cause vasoconstriction rather than vasodilation and infers 
that vasoconstriction peptides, such as angiotensin II and endothelin-1, can be substrates 
for NEP.1701 This explains why NEP inhibitors, such as candoxatril, thiorphan, and 
phosphoramidon increase blood pressure in normotensives.[71]
NEP is also involved in the metabolism o f kinins. In most tissues, NEP accounts 
for only a small portion o f the metabolism o f kinins, but in human cardiac tissue, NEP 
accounts for nearly half o f the metabolism o f bradykinin.1721 W hen ACE is inhibited, 
however, NEP becomes a major pathway for bradykinin metabolism. In experimental
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studies, the reduction o f ischemia and reperfusion damage after NEP inhibition is kinin- 
mediated.1731 Interestingly in hypertension, the selective NEP inhibitor candoxatril (Fig. 
4.3) led to only minimal blood pressure reduction, whereas its combination with an ACE 
inhibitor caused a marked decrease in blood pressure.1741
MeO
Figure 4.3 Structure o f  Candoxatril.
D. Combined ACE and NEP Inhibition
In many cardiovascular diseases, an array o f regulatory mechanisms is involved, 
making drugs with multiple modes o f action promising. In other words, using a single 
drug for a single target is not as beneficial when the system has more than one target to 
hit. Because ACE inhibition leads to normalization o f the physiological effect o f  ANP 
and NEP inhibitors lower blood pressure more effectively in salt-and-volume-dependent 
than in renin-dependent forms o f hypertension, the combination o f ACE and NEP 
inhibition may be especially useful in hypertension and CHF.1751 Indeed, hypertension 
and CHF, the hemodynamic and renal effects (i.e., urine volume and sodium excretion) 
achieved after simultaneous inhibition o f ACE and NEP are more pronounced than after 
selective inhibition o f both enzymes.1751’1761
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The synergistic effect o f combined NEP and ACE inhibition is based on similar 
modes o f action, including blockade o f  angiotensin synthesis and simultaneous 
unmasking and potentiation o f the effects o f peptides such as ANP, BNP, and bradykinin 
(by preventing their degradation), in turn inducing vasodilation and diuresis and 
improving myocardial function (Fig. 4.2) ,[77]
Unfortunately, ACE and NEP structure elucidation has been a very difficult task 
due to size and heavy glycosylation.1-455 At present, ACE structural information is not 
useful for inhibitor design, and the most relevant factors in inhibitor preparation remain 
in knowledge o f the enzymes subtrate specificity, the use o f computer programs to 
flexibly superimpose potent conformationally restricted inhibitors (pharmacophore 
development), coupled with an understanding o f the catalytic mechanism.[78] Our 
understanding o f the hydrolytic mechanism o f these physiologically important 
mammalian peptidases, and their interaction with inhibitors, has been aided greatly by 
study of the related bacterial endopeptidase thermolysin (TLN). Although the amino acid 
sequence o f thermolysin is not necessarily related to the sequence o f other zinc-requiring 
peptidases such as ACE and NEP,t?9J there is increasing evidence that the active sites o f 
there zinc enzymes have common features.l8°E8,ri82] such5 recent X-ray structures o f 
thermolysin-inhibitor complexes have proven useful in elucidating the mode o f binding 
o f related zinc peptidases including ACE and NEP.^831 Moreover, commercial availability 
and cost makes thermolysin easier to obtain and study. Therefore, understanding 
thermolysin’s mode o f action and interaction with potential inhibitors can aid better 
understanding o f  ACE and NEP.
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E. Thermolysin
Thermolysin (TLN) is a thermostable zinc-containing endopeptidase o f  molecular 
weight 34,600 isolated from the thermophilic bacterium Bacillus thermoproteolyticus.[841 
In order to understand the catalytic mechanism o f thermolysin, its crystal structure has 
been determined, both in its native state and in complexes with inhibitors.1851 TLN is 
related to other peptidases such as ACE, NEP, collagenase, and enkephalinase, which 
have been recognized to play important roles in cellular and hormonal metabolism.1841 In 
addition, thermolysin has proven to be an advantageous system for the detailed 
evaluation o f protein-ligand binding interactions.1861
TLN is particularly suited for studying the mechanism o f zinc-promoted peptide 
hydrolysis because a variety o f crystallographic, inhibitor, substrate, and chemical 
modification data are available. Importantly, the crystal and solution conformations 
appear to be very similar on the basis o f available experimental comparisons,1871 and 
moreover, the crystalline enzyme still hydrolyzes peptides. The relevance o f the crystal 
structure is further enhanced by the fact that thermolysin changes very little upon binding 
numerous inhibitors; this feature makes thermolysin a good model to study the hydrolysis 
mechanism by zinc peptidases.1871
The crystal structure o f thermolysin together with computer graphics analysis o f 
the active site, and the x-ray structure o f a N-carboxymethyl dipeptide inhibitor1881 have 
led to a proposal o f  its mechanism (Fig. 4.4).1891 The protein consists o f two spherical 
domains with a deep left cleft in the middle, which constitutes the active site. In its 
native state, thermolysin has a single water molecule bound to the zinc ion. The 
inhibitor, N -(l-carboxy-3-phenylpropyl)-l-leucyl-l-tryptophan, has been observed to
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bind to thermolysin with the carboxyl group close to leucine interacting with zinc. In 
addition, the leucyl side chain was found to be required by the active site due to its 
nestled location in the hydrophobic specificity pocket.
Together with three ligands from the protein (Glu-166, H is-146, and H is-142), the 
zinc coordination is essentially tetrahedral. An incoming peptide is presumed to displace 
zinc bound water molecule toward Glu-143, forming a pentacoordinate complex at Zn. 
The water molecule, activated by the combined influence o f  the metal ion and Glu-143, 
attacks the carbonyl carbon to form tetrahedral intennediate. The tetrahedral 
intermediate is presumed to form a bidentate complex with the zinc and is stabilized, in 
part, by hydrogen bonds from His-213 and Tyr-157. Glu-143 accepts the proton from the 
activated water molecule and is presumed to subsequently donate the proton to the 
scissile nitrogen, although proton donation by solvent water is not excluded as an 
alternative. Glu-143 is presumed to also shuttle the remaining proton from the hydroxyl 
derived from the nucleophilic water molecule to the generated primary amine to yield the 
two peptide productsJ87̂
55
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
H
substrate
* J V . water 0 *
G fu143
0
Figure 4.4. Proposed mechanism o f thermolysin-catalyzed hydrolysis. 
The reaction proceeds by the attack o f the zinc-bound water molecule on 
the scissile bond. The resulting tetrahedral intermediate, with enzyme 
residues involved in its stabilization, is shown. This subsequently 
decomposes to yield the products. Adapted from Matthews, the 
nomenclature used for the individual amino acids (P i, Pi', etc.) o f a 
substrate and the subsites (Si, S f, etc.) o f the enzyme is that o f  Schechter 
and Berger. Amino acid residues o f substrates numbered Pi, P2 , etc. are 
toward the N-terminal direction, and P f, P2', etc. are toward the C-terminal 
direction from the scissile bond (figure from Fernandez et al. 2001).
F. Design of Dual ACE/NEP Inhibitors
As previously stated, both ACE and NEP are zinc M M P’s with similar 
mechanism o f actions and, hence, some structural similarities. The region o f the enzyme 
where catalysis occurs are almost identical: the zinc, the zinc binding atoms, and nearby 
catalytically important glutamic acid o f each enzyme could readily be superimposed on
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the corresponding atoms o f the other protease.[78i Most relevant to inhibitor design, the 
regions o f the structure which mimic the scissile bond o f the substrate also adopt a 
common conformation. However, beyond this region, the conformation that the inhibitor 
backbone and side chains adopt is significantly different. These differences reflect the 
variation in the shapes o f the binding site o f the different enzymes. These variations in 
binding site topology are responsible, at least in part, for the differences in substrate 
specificity. ̂
ACE is a dipeptidyl carboxypeptidase usually cleaving the C-terminal dipeptide 
residue o f its substrates. Potent ACE inhibitors have been designed to mimic both di- and 
tripeptides. Extensive structure activity studies o f ACE inhibitors revealed three 
important structural features required for tight binding to ACE: a functional group acting 
as a zinc binder, an amido carbonyl group, and a C-terminal carboxylic acid.
NEP has a broader substrate specificity than ACE and can act both as an 
expopeptidase and as an endopeptidase. This behavior is reflected in the relatively large 
structural variations observed with NEP inhibitors. Some potent NEP inhibitors resemble 
tri- and tetrapeptides, while other smaller inhibitors are dipeptide mimics. The features 
critical for an NEP inhibitor include the following: a zinc binding group, a Pi 
hydrophobic group, and an amide group (or amide surrogate) available for forming two 
hydrogen bonds. A terminal carboxylic acid group seems advantageous, although it is 
not essential nor is its precise position as critical at it is for ACE inhibitors.
Therefore, in order for a single molecule to inhibit both ACE and NEP, it must 
possess a zinc binding group. The atoms connecting this group to the rest o f  the inhibitor 
must be able to adopt the common conformation found in the zinc M MP x-ray data. In 
addition, this molecule must include the functional groups required for tight binding to
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each enzyme, and these groups must be able to adopt the conformation appropriate for 
the different binding sites.
Conformational restriction is an attractive strategy to maximize the binding o f an 
inhibitor to a specific active site by reducing the loss o f conformational entropy 
experienced when a flexible molecule is removed from solvent and forced to fit into a 
binding site.1901 However, at first glance, this approach does not appear suited for the 
design o f dual inhibitors. Indeed, an inhibitor which is to efficiently occupy the binding 
sites o f two structurally different enzymes cannot be totally rigid. To overcome this 
problem, a molecule can be designed to include conformational constrained sections 
designed to interact with certain areas in the binding site o f each enzyme. These 
structural units can then be connected by a flexible hinge, allowing the entire molecule to 
adopt conformations complementary to the active site o f each enzyme.
The active site o f an enzyme performs the twofold function o f  binding the 
substrate and catalyzing the reaction. The efficiency o f these actions determines the 
overall activity o f  the enzyme towards the particular substrate, which in turn determines 
the specificity o f the enzyme. In order for an enzyme to be selective its active site is 
composed o f “sub sites,” each accommodating one amino acid residue o f  the substrate. 
The substrate is visualized as fitting into the groove, binding to several sub sites of 
specific geometry (Fig. 4.5).[91]
Although NEP and ACE have significant analogies in their active sites, as shown 
by their capacity to cleave in vitro identical peptides at the same bondJ92' The selectivity 
o f molecules inhibiting these enzymes results from subtle differences in the active site of 
both peptidases. Efficient NEP inhibitors preferentially contain aromatic residues in the 
Pi p o s itio n ,^  and most ACE inhibitors are characterized by a small residue (Ala) in the
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Pi position and a cyclic amino acid (Pro) in the P2 p o s i t i o n H o w e v e r ,  it has been 
possible to design dual inhibitors o f these peptides by introducing more hydrophobic 
residues in the selective inhibitor o f  NEP and have shown relatively good affinities for 
both enzymes.[94]
P oint o f  cleavage
Figure 4.5. Schematic representation o f an enzyme-substrate complex. The active site 
o f the enzyme is composed of 6  “subsites”, ( S3-S3 ), located within the catalytic site of 
the enzyme. The peptide positions, ( P3-P3 ), on the peptide substrate are counted from 
the point o f  cleavage and thus have the same numbering as the subsites they occupy.
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Figure 4.6. Structure of RB 105.
Recently, more potent dual inhibitors containing hindered substituents have been 
designed giving new information about the structures o f the binding domains o f each 
enzyme. Thus, the development o f RB 105 [(2S,3R)-HSCH2CH(CH3CHCH3)Phe)CO- 
Ala]'95' has shown that the Si o f both peptidases is able to accommodate constrained 
moieties such as a p-methylbenzyl group. However, conformational analysis o f RB 105 
(Fig. 4.6) and its derivatives, to determine thermodynamically acceptable overlaps 
between stable conformers o f these inhibitors and the ACE pharmacophore, designed 
from rigid selective inhibitors, showed that the presence o f the |3-methylbenzyl group in 
the P| position, precludes the presence o f bulky residues in the P2 position.'951 Recently, 
a great number o f molecules containing polycyclic residues at the P2 position have been 
described, showing that NEP seems to possess, like ACE, a large S2 dom ain,'951 in 
agreement with earlier observations.'97' Taken together, these data support the idea that 
the Si and S2 sub sites o f NEP and ACE constitute hydrophobic domains which could be 
efficiently occupied by cyclic or linear structures.'94],'93]
Since the specificity o f ACE and NEP is essentially due to van der Walls and 
ionic interactions between the Si , S2 , and S3 sub sites o f NEP and the Si, Si , and S2 sub
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sites o f ACE a working template for Pi, Pi , and P2 should be established: (1) the 
substrate has to have a zinc binding group, (2) the Si pocket in both enzymes can 
accommodate a large hydrophobic residue, (3) the Si sub site o f ACE and S2 sub site of 
NEP are also hydrophobic but do not seem to be as open as the S i sub site in both 
enzymes, (4) although not as important as the previous three, the S2 sub site o f  ACE and 
the S2 sub site o f  NEP favor a cyclic peptide, and (5) a terminal carboxylic acid.
G. Transition State and Enzyme Catalysis
The term transition state (TS) refers to the configuration along the reaction 
coordinate that a species must pass through on its way to product formation. The 
transition state corresponds to the highest energy state in the course o f  a reaction; it is a 
dynamic, reactive and unstable state in which bonds are only partially formed or broken. 
According to transition state theory, the physical entities under consideration during a 
reaction are the reagents, or ground states, and the most unstable species in the reaction 
pathway, the transition state(s). The importance o f transition state theory is that it relates 
the rate o f a reaction to the difference in Gibbs Free Energy (G) between the transition 
state and the ground state. This is an important consideration when comparing the 
relative reactivity o f  pairs o f substances or the rates o f a given reaction under different 
sets o f conditions.
The difference in height on the energy surface between the starting materials and 
the transition state is the reaction’s activation energy (or AG *), and is the energy barrier
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Figure 4.7. Effect o f catalyst on reaction pathway.
that must be overcome before the reactants can convert to product. The higher a 
reaction’s activation energy is, the more difficult the path to products. An enzyme, 
however, can speed up a reaction by lowering the activation energy thus providing a 
smaller energy “hill” in the reaction pathway (Fig 4.6).^98] Thus, enzymes function as 
catalysts in reactions, meaning that they alter the rate o f  a reaction without themselves 
undergoing change. The enzyme is able to function as a catalyst by converting the 
substrate into a specific product through the formation o f a reactive TS. One o f the 
enzymes primary functions in its role as a ca ta lyst, however, is not its ability to strongly
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s
p
P = products
EP = enzyme prod, complex
ES — enzyme substr. complex
S = substrate
Figure 4.8. Energy levels in catlysis vs. normal reaction
bind the substrate or the product but rather its ability to discriminate between substrate, 
product and transition state. In 1946, Linus Pauling suggested that an enzyme binds more
the transition state, it is stabilized and as a result, less energy is needed to access this 
structure. The energy barrier is subsequently lowered and the reaction is generally 
accelerated -  often by factors of several orders o f magnitude (Fig. 4.8). The enzyme’s 
effect is catalytic because the molecules immediately diffuse away from the active site 
following product formation, enabling the enzyme to bind and transform new substrates 
repeatedly.^001 To provide for the catalytic affinity, interactions between the enzyme and 
the substrate are extensive with a specificity reflected in the transition stated10' 1 The 
binding interactions are quite numerous and can include hydrophobic, ionic, n-stacking 
and hydrogen bonding.
strongly to the transition state than to the reactants or products.1" 1 When enzymes capture
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H. Transition State Analogues
The concept o f transition state analogues has been very useful in designing potent 
enzyme inhibitors .*1011 Such transition state analogues are designed on the assumption 
that structures which mimic the normal transition state have optimal interactions with the 
enzyme in that site. During catalysis, favorable binding interactions, not available to the 
ground-state enzyme-substrate complex, develop as the enzyme-substrate transition-state 
complex forms. These enhanced binding interactions assist in lowering the activation 
energy o f the reaction, and hence in accelerating the enzymatic rate .*1021
TS analogue inhibitors take advantage o f these additional interactions by 
possessing, in their stable structures, key structural elements o f  the unstable enzyme- 
substrate transition-state complex.*103* Pauling predicted that it would be possible to 
utilize transition state analogues as enzyme inhibitors.1*"* He predicted that, given a 
reaction for which an enzyme exists, a stable substance might mimic the native, reactive 
transition state in shape and charge. Such a transition state analogue should bind very 
tightly to the enzyme and inhibit its catalytic action by filling the binding site at its most 
complementary state, and thereby preventing the active site from binding to its true 
substrate.*100* This theory has been validated over the last twenty years, as a significant 
number o f compounds have been synthesized that behave as TS analogues in just the 
same manner Pauling predicted.*101* An example o f the depiction o f enzyme action is 
supported by studies that show that stable mimics o f transition states (such as 
phosphonates) are held tightly by enzymes that employ the putative mechanism (Fig 
4.9).*101* In this mechanism, a phosphorus atom has been substituted for a reaction
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Transition state
stable transition state analog 
Figure 4.9. Hydrolysis o f ester and phosphonate analog
carbonyl in the transition state’s tetrahedral ensemble, yielding a stable compound known 
as a phosphonate ester. The distribution o f charge on the phosphonate oxygen atoms of 
the molecule resembles that o f the TS. In addition, the phosphorus-oxygen bonds are 
about twenty percent longer than ordinary carbon-oxygen bonds, which enables the 
analogue to mimic the elongated bonds o f the TS . 1'00-1 Importantly, phosphorous esters 
and amides by virtue o f their sp‘ hybridized center, closely resemble the TS achieved 
during the hydrolysis o f certain carbonyl compounds.[104] As a result, many o f these 
phosphorus-based analogues have been used as enzyme inhibitors1' 05^11061 and as haptens 
for the production o f catalytic antibodies.[100]
The arrival o f stable TS analogues, conceived to mimic the structure o f an 
intermediate in the path o f a substrate’s transformation to product, have made it possible
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to examine the degree o f  enzyme binding/distortion energy, and to probe the specificity 
and selectivity o f this interaction. Most TS analogues behave as potent inhibitors 
because, unlike the native substrate, they ar.e not transfonned into product and remain 
tightly held in the catalytic domain, thereby inactivating the enzyme. Some enzyme 
inhibitors have been used to study the role o f individual enzymes, to understand enzyme 
mechani sms, and to aid in the development o f pharmacological and agricul tural 
agentsJ107-1 Among them, peptides containing a transition state-analogue in place of a 
hydrolyzing amide bond have received considerable attention. Typically, peptide TS 
analogues contain a phosphonoamidate or a sulfonamide moiety,1108] which show the best 
resemblance to the TS during the hydrolysis o f the amide bond from both a steric and 
electronic point o f view (Fig. 4.10). These TS analogues have been used in the 
development o f protease inhibitors such as thennolysin, renin and pepsin.
HO O' O, O' O O
a b c
R = alkyl, R, = alkyl, R2 = H, alkyl
Figure 4.10. Amide bond hydrolysis intermediate and 
two TS analogues.
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I. Phosphorus-Containing TS Analogues as Thermolysin Inhibitors
Phosphonate: X = O, Rj = OR, R2 = alkyl, aryl 
\ \  /  Phosphinate: X = O, R] = R2 = alkyl, aryl
^  P \  Phosphonamidate: X = O, X = O, R] = NHR, R2 = alkyl, aryl
^ 1  ^ 2  Phosphoramidate: X = O, X = O, R] = NHR, R2 = OR'
Figure 4.11. Phosphorus-containing monoacids o f TS analogous
Some o f the most potent inhibitors o f thermolysin are transition state analogues 
that incorporate phosphorus-containing tetrahedral groups capable o f  binding to the 
active site zinc in a bidentate fashion.^l09Rn0l
Phosphonate, phosphinate, phosphonamidate and phosphoramidate analogues 
(Fig. 4.11) designed to the same TS show different binding propensity to thermolysin.[84j 
The enhanced binding and inhibitory potency o f the phosphonamidate analog has been 
attributed to specific hydrogen-bonding by the am idateJ107J Grobelny and co-workers 
noted that the binding energy difference was due to increased basicity o f  the 
phosphonamidate anion (better ligates the active zinc atom), whereas solvation effects 
were negligible .^1
A well known phosphorus-containing inhibitor used to probe the mechanism of 
therm olysin is phosphoram idon [N -(a-L-rham nopyranosyloxyhydroxyphosphinyl)-L-
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R = OH
N
H
O COpH
NH
Figure 4.12. Phosphoramidon
leucyl-L-tryptophan] (Fig. 4.12). This naturally occurring potent inhibitor 
(K3 = 2.8 x 10'8), consists o f a rhamnose sugar group attached to a leu-trp moiety through 
aphosphate.[!l2] The phosphoramidon-thermolysin complex was crystallized, and showed 
monodentate Zn-ligation to one o f the phosphate oxygen’s, 2.0 angstroms form the zinc 
atom, resulting in a tetrahedral complex which closely resembles the transition state 
during the catalytic process.1891 Additionally, the crystal reaffirmed that the N-phosphoryl 
group mimics a hydrated peptide since it was seen that the P -0  bonds were only slightly 
longer than the corresponding C -0  bonds, and both the phosphoryl group and a hydrated 
peptide have tetrahedral geometries.1[87] Interestingly, removal o f the rhamose moiety 
from phosphoramidon resulted in a slightly tighter binding inhibition indicating the sugar 
is not essential for thennolysin recognition.
Based on the effectiveness o f phosphoramidon as an inhibitor o f  thennolysin, a 
series o f related phosphoramidates and phosphonamidates have been synthesized and
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Figure 4.13. Bertenshaw’s truncated version of phosphoramidon.
proved to be potent inhibitors not only o f thermolysin, but also o f other zinc peptidases 
including carboxypeptidase A, endothelin converting enzyme (ECE), and ACE.[II3]'[I14* 
Bertenshaw truncated the phosphoramidon structure in an attempt to inhibit ECE (Fig. 
4.13). The study found that the sugar moiety was not essential for anti-ECE activity.*1 151 
Previous studies*113 ' also reaffirmed that the rhamnose moiety was o f very little 
importance for the inhibition o f ACE or ECE, whereas the phosphoryl group o f 
phosphoramidon was a absolute requirement. Furthermore, the tryptophan residue of 
phosphoramidon appeared to be important for the ECE inhibition while thermolysin 
inhibition seemed to depend greatly on the leucine residue. It was concluded that in vivo 
ECE and thermolysin differ only in the way they recognize phosphoramidon.
J. Phosphorus Nomenclature
Phosphorus compounds can exist as di, tri, tetra, and pentavalent species. The 
nomenclature o f  various substituted pentavalent organophosphorus compounds are as
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follows. A phosphate has four oxygen’s directly linked, a phosphonate has three 
oxygen’s and one carbon, an H-phosphonate or phosphinate has two oxygen’s, one 
carbon, and one hydrogen bonded to phosphorus. A phosphoryl is a general term 
referring to solely the phosphorus-oxygen double bond (P=0) with the term “thio” added 
as a prefix when oxygen is replaced by sulfur.
It is important to recognize that when the four substituents around the central 
phosphorus atom are different, the phosphorus becomes a chiral center. This 
characteristic is important since it will add a chiral center in the compound where it will 
most likely ligate with the zinc atom in the metalloproteases. W ith enantioenriched 
compounds tested with thermolysin new information can be divulged about the 
relationship o f the inhibitor and the 3D structure o f the enzymes active site.
K. a-Aminophosphonic Acid and the Pudovik Addition
The phosphorus analogs o f a-aminocarboxylic acids, a-am inophosphonic have 
attracted significant attention owing to their synthetic and biological value as both 
agrochemical (herbicides, pesticides, growth regulator in plants) and medicinal 
(antibiotics, antivirals, enzyme inhibitors) products with broad applications.1-1161 The 
bioactivity o f these compounds is known to be strongly dependent on their absolute 
configurations, and some methods, including diastereomeric1’171 and chemoenzymatic 
resolutions1" 81 and asymmetric synthesis,1" 91 are available for the synthesis o f  optically 
pure a-am inophosphonic acids. O f the various methods for the preparation o f a -  
aminophosphonic acids, the most general route is the Pudovik11201 addition o f
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dialkylphosphonate to a Schiff base, followed by hydrolytic or reductive cleavage o f 
diester precursors to either the mono or diphosphonic acid.
The Pudovik addition is the addition o f esters o f phosphorous (III) acids with 
unsaturated systems like carbonyl’s, Michael adducts, or imines producing dialkyl N- 
substituted, a-substituted, and a-aminophosphonates. The reaction is attributed to the 
slow tautomerism o f the pentavalent phosphonate to the more reactive tricoordinate 
phosphite (Fig. 4.13). The more nucleophilic tricoordinate phosphorus atom attacks the 
electrophilic carbon o f  the unsaturated system, forming a P-C bond, and generating a 
positive charge on the phosphorus atom. A nonbonding electron pair o f  the hydroxyl 
group fonns a pi bond with phosphorus, neutralizing the phosphorus atom. Subsequent 
proton transfer from the protonated phosphonyl to the amide anion yields the desired 
products. The addition o f dimethyl phosphite to asymmetrical imines, carbonyl’s, and 
Michael adducts results in a chiral carbon bonded to phosphorus (Fig. 4.13). 
Unfortunately, the addition usually produces a racemic solution due to the slow reaction 
time and a reaction center that can be attacked equally on either side o f  the eletrophilic 
carbon (Fig. 4.13). The resulting racemic mixture has to then be separated by either 
diasteromeric or chemoenzymatic resolution.
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Figure 4.14. Dimethyl phosphite tautomerism between pentavalent and trivalent 
phosphorus. The reactive trivalent phosphorus attacks the electrophilic carbon o f 
imine [1] leads the subsequent generation o f the phosphonium ion [4]. The 
nonbonding electrons o f the hydroxyl group form a double bond with phosphorus to 
give intermediate [5] which then looses a proton to afford a-am inophosphonate
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L. Asymmetric Synthesis
The asymmetric synthesis o f organophosphorus compounds is a relatively new 
field, which has developed mostly during the past two decades.11191 For the preparation o f 
enantiomerically homogenous molecules, chemists have basically two options. The 
molecules can either be synthesized in racemic form and resolved, or the synthesis can be 
performed in an enantioselective fashion so as to produce enantiomerically enriched 
products. Steroselectivity in the synthesis o f chiral molecules can be realized by 
asymmetric induction o f chirality (asymmetric synthesis)'121' or via kinetic resolution.'122'
The term ‘asymmetric synthesis’ was first used in 1894 by Emil Fisher and 
defined in 1904 by W. Markwald as a reaction which produces optically active 
substances from symmetrically constituted compounds with the intermediate use of 
optically active materials but with exclusion o f analytical processes. Morrison and 
M nsher'121' consider the asymmetric synthesis as a reaction in which an achiral unit in an 
ensemble o f substrate molecules is converted by a reactant into a chiral unit in such a 
manner that the steroisomeric products are formed in unequal amounts. Kagan and 
F iaud'122' suggested that, “kinetic resolution can be defined as a process in which one of 
the enantiomer constituents o f a racemic mixture is more readily transformed into a 
product than the other (enantioselective reaction).” I f  the Pudovik reaction is stopped 
before completion, for example unequal amounts o f the diasteromerically substituted 
organophosphorus compounds should thus be obtained. The remaining unreacted starting 
material will also exhibit optical activity.1' 23'
Pentavalent tetracoordinate organophosphorus compounds can exist in optically 
active states and are configurationally stable.'124' On the basis o f optically active
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organophosphorus compounds, syntheses o f different chiral organic compounds have 
been developed in which asymmetric induction involves; the transfer o f  chirality from 
phosphorus to another center, an asymmetric addition to an achiral molecule due to 
sterics or kinetics, and reactions in the course o f which the formation o f a new 
stereogenic center is accompanied by elimination o f the phosphorus moiety.
Silyl phosphite esters (RO^POSiRN have been shown to be remarkably versatile 
phosphorylating reagents.[l25] Chiral silylated organophosphorus reagents can be used in 
the asymmetric phosphorylation o f prochiral unsaturated organic substrates such as 
aldehydes. One is the asymmetric variant o f the Abramov reaction. This was applied to 
compounds possessing C2-symmetry where only a single stereoisomeric form exists for 
the silylated organophosphorus (II) reagent and hence only two possible isomers can be 
produced in the reaction with benzaldehyde.1-126̂ 1271
The silylphosphite compounds 46 have been synthesized by the reaction of 
binaphthalatochlorophosphites wR3SiOH.11281 These chiral compounds are active 
asymmetric phosphonylating reagents. They undergo the Abramov reaction with 
benzaldehyde at rt to afford new silyloxy esters 47 in high yield and with good 
stereoselectivity. Silylphosphites derived from chiral (+)-dimethyl L-tartaric esters 48 as 
auxiliaries have been obtained, however, they are not sufficiently useful because they do 
not react very cleanly with benzaldehyde (Scheme. 4 .1 )J129̂
The 2-triorganosiloxy-l,3,2-oxazaphospholidines 49 undergo the Abramov 
reaction with benzaldehyde at rt to afford new esters in high yield and with good 
stereoselectivity. Recrystallization o f diastereomeric mixtures from pentane affords a- 
siloxyphosphonate esters 50 as white crystalline solids in up to 88% isolated yield and 
95% isomeric purity.[130],[ 1311 The reaction is kinetically controlled and the transfer o f the
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silyl group to the oxygen is intramolecular, with results in retention o f  relative 
configuration at the phosphorus atom (Scheme 4.2).11321
O
R3SiOH/NEt3 * PhCHO <RO >p
(R 0 ) 2PC1 ---------------------► (RO )2P------ SiR3 ----------------►
46 37 Ph
(R 0 )2P
Scheme 4.1. The Abramov reaction with binaphthalatochlorophosphites and 
benzaldehyde.
Ph. Ph,
Me
-0.
N
s PhCHO
P -^ O S iR ^  -------------
' °  y O
P^ ^OSiR3
\
Me
N
\
Me Me
Ph
49 50
Scheme 4.2. The Abramov reaction with 2-triorganosiloxy-l,3,2- 
oxazaphospholidines and benzaldehyde.
The reaction o f  dialkylphosphite anions with aldehydes is a method for the 
synthesis o f  a-hydroxy phosphonamides. As stated previously, the absolute
75
OSiR3
48
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
configuration at the a-position in substituted phosphonic acids is very important for 
biological activity.
Spilling and co-workers investigated the use o f chiral phosphorus compounds as 
reagents for symmetric synthesis, and have developed a method for the asymmetric 
synthesis o f a-hydroxyacid derivatives formed by addition o f chiral phosphoric acid 
diamide to aldehydes. Addition o f aldehydes to chiral phosphoric acid anions in THF 
solution proceeds stereoselectively to a-hydroxyphosphonamides 51 in good yield and 
good stereoselectivity (54-93% c/e).[133] The diastereoselectivity was strongly dependent 
upon the diamide used and ranged from poor to good.[134] It was found that the reaction 
proceeds irreversibly and under kinetic control. The phosphonamides were hydrolyzed 
with aqueous HC1 in dioxane to provide a-hydroxyphosphonic acids 52 (Scheme
4  3 )  [ 134 ] , [ 135 ]
Gordon and Evans described the condensation o f diastereoisomeric 2-methoxy- 
1,3,2-oxazophosphites with a variety o f aldehyde-boron trifluoride etherate complexes 
resulting in diastereoisomerically enriched mixtures o f a-hydroxy-2-oxo-1,3,2- 
oxazaphosphorinanes 53 (75:25 diastereomeric ratio) (Scheme 4 .4 )J132̂
76
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Scheme 4.3. Asymmetric Pudovik addition with chiral phosphoric acid diamide to 
aldehydes.
PhCHO, Lil/BF
N aO H
Scheme 4.4. Condensation of diastereoisomeric 2-methoxy-1,3,2- 
oxazophosphites with benzaldehyde-boron trifluoride etherate complexes.
Optically pure samples o f both enantiomers o f 55a and 55b were obtained by the 
asymmetric induction method, described initially by Gilmore and M cBride.11361 The 
synthesis involved preparation of Schiff s bases 54 from R-(+)- and S(-)-l- 
methybenzylamine and corresponding aldehydes, addition o f diethyl phosphite,
31hydrolysis, and hydrogenolysis (Scheme. 4.5). By P NMR analysis o f crude esters 55 
revealed that diethyl phosphite addition, when carried out at rt without solvent yielded
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H
^  / ° H 
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P— OH ^  / ° H P— OH
NH NH
55a 55b
Scheme 4.5. Asymmetric induction method.
55a and 55b as mixtures o f diastereoisomers formed in ratios o f 6:1. At higher 
temperatures the induction was less pronounced, e.g. heating 54 with diethyl phosphite at 
140EC without catalyst, as specified by Gilmore and McBride, produced a mixture of 
diastereoisomeric 55a and 55b in a ratio o f 2:1. Mechanistic rationale for asymmetric 
induction stems from the formation of the Schiff base and sterics hindering the addition 
o f diethyl phosphite on the bulky phenyl side o f the compound (Fig. 4.15). Thus, heating 
the reaction would provide the Schiff base with the energy needed to be in a higher 
energy conformation and leaving both sides open for attack with diethyl phosphite.
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Figure 4.15. Addition o f diethyl phosphite to the Schiff base 
formed from benzaldehyde and R-(+)-phenethylamine. Sterics 
from the phenyl ring hinder attack o f diethyl phosphate vs. the 
attack on the methyl side.
M. a-Aminophosphonothioic Acids
Despite all o f the advances in the preparation o f enantioenriched A PA ’s, the 
syntheses o f the corresponding phosphonothionate analogs o f A PA ’s, a -
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aminophosphonothioic acids, has not been as thoroughly researched. Phosphorothioic 
acids are sulfur-containing analogs o f phosphate groups in nucleoside chemistry and 
because the thiol group imparts chemical characteristics that differ from the
NHFh NHR-i
thiono-tautomer thiolo-tautomer
1: a-aminophosphonothioic acid (R = H)
2: a-am inophosphonothioate ester (R = alkyl)
Figure 4,16. General structures o f a-aminophosphonothioic acids (1) and 
phosphonothioate esters (2) and their possible tautomers.
corresponding phosphate group (i.e. nucleophilicity, ligand characteristics, etc.) show 
value as new substrates. Such novel properties could also be beneficial additions to TS 
analogs o f enzymes. Furthermore, the tautomeric non-equivalent form o f the a - 
aminophosphonothioic acids (thiono-thiolo equilibrium: Fig 4.16) and the capability to 
generate a new asymmetric center at phosphorus when in the monoester form, provides 
further benefits for this class o f compounds.
The use o f Lawesson’s reagent (2,4-bis(4-methoxyphenyl)-l,3-diathia-2,4- 
diphosphetane-2,4-disulfide) to convert the P = 0  for P=S would be the most direct route 
to form an APT A. Unfortunately, the preferred reactivity o f the thionating agent at the 
amino or amine protecting group makes this route extremely difficult. Forming the
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asymmetric APTA monoester by displacement of the phosphorus ester group by SFT fails 
due to competing dealkylation reactions at the phosphoais ester groups. As previously 
stated, dialkyl phosphites add to imines (prepared from chiral amines) with stereocontrol 
to afford a-aminophosphonates. From previous work in this lab, it was found that 
dimethyl thiophosphite (DMTP) adds rapidly and in high yield to a variety of 
electrophiles including imines. By adapting the DMTP addition to imines with chiral 
auxiliaries to provide the a-aminophosphonothionates bearing an enantioenriched a - 
carbon center (Scheme 4.6) would allow direct access to the desired A PTA’s via 
hydrolysis o f the ester.
OMe
R S M e o m ^ S
I  + II  ► '  I
R ^ N ^ R  H - ' V 0Me r^ n ^ r
OMe R N R
R = alkyl, aryl a-am inophosphonothionate
Scheme 4.6. Addition o f dimethyl thiophosphite to chiral imines.
N. Statement of the Problem
Phosphorus-containing analogues have made significant contributions to our 
understanding o f TS structure, however, several drawbacks to their application (resulting 
in deficits in current understanding) do remain. Some o f  these drawbacks include; (1) a 
lack of an essential hydrogen-bonding or solvation interaction in some phosphonates and 
phosphinates leaves then ineffectual, (2) instability to acid for many phosphonamidates,
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and, (3) when used as haptens, failure to result in antibodies with substantial catalytic 
activity suggesting that key elements in binding amidases may be absent in 
phosphonamidates J 106̂
Despite these drawbacks, phosphorus-containing analogues do offer useful 
advantages. Certain phosphorus esters and amides, by virtue o f  their sp3 hybridized 
center, closely resemble the transition state achieved during the hydrolysis o f certain 
carbonyl compounds. Another important advantage is the use o f  3IP NMR, a sensitive 
nucleus, capable o f revealing highly diagnostic chemical and biochemical information.
In addition, x-ray techniques as in the case o f the crystal structure o f  a thermolysin- 
phosphoramidate TS analogue, has given tremendous insight into the TS-protein 
interaction. Doubtless, the systematic design and use o f phosphorus-containing analogues 
will remain a promising path toward more specific and potent inhibitors (or probes) o f 
protein structure and function.
It is well established that a-aminophosphonic acids, the phosphorus analogs o f 01- 
amino acids, exhibit novel biological properties. Substitution o f  a sulfur atom in place o f 
a phosphoryl oxygen forms a-aminophosphonothioic acids (A PTA ’s), a new class o f 
compounds in which the carboxyl group o f an a-am ino acid has been replaced by a 
phosphonothioic acid moiety. This alteration introduces chirality at the phosphorus 
center, as observed by the tautomerically non-equivalent P[137]SH = P(S)OH 
equilibrium. As a result o f this unique asymmetric center, A PTA ’s are predicted to 
exhibit different chemical properties from both a-am inophosphonic acids and the 
corresponding a-am ino acids. Since a-am ino acids serve as building blocks in several
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structures im portant to biological activity, APTA’s could have broad applications as 
amino acid mimics.
The proposed research will devise new methods for the preparation o f APTA’s, 
use the new methodology to prepare peptide mimics o f the TS o f zinc M M P’s, and 
preliminary testing o f  the substrates as inhibitors o f NEP and AGE.
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Chapter 5
Synthesis
A. Dimethyl Thiophosphite
The transformation o f dimethyl phosphite 56 to dimethyl thiophosphite 57 was 
brought about with Lawesson’s reagent. Lawesson’s reagent acts as a thionating agent, 
converting carbonyl oxygen into sulfurs.[138] The mechanism o f the reaction o f 
Lawesson’s reagent with carbonyl compounds is believed to occur through Wittig type 
intermediates, w ith the formation o f 2,4,6-tris(p-methoxyphenyl)-1,3,5- 
trioxatriphosphorinane 2,4,6-trisulfide (Fig. 5.1). Lawesson’s investigation o f the 
stoichiometry o f the reaction revealed that in facile reactions proceeding as low 
temperatures, resulting in little loss of Lawesson’s reagent to decomposition, the ratio of 
0.5:1.0 reagent to reactant yields near quantitative thionation with attendant formation of 
the intermediate trimer 2,4,6-tris(p-methoxyphenyl)-l,3,5-trioxatriphosphorinane 2,4,6-
Lawesson's reagent
Figure 5.1. Law esson’s reagent and the known trimer 2,4,6-tris(p-methoxyphenyl)- 
1,3,5-trioxatriphosphorinane 2,4,6-trisulfide formed during thination o f carbonyls using 
Lawesson’s reagent.
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Schem e 5.1. Synthesis o f dimethyl thiophosphite (57) from 
dimethyl phosphite.
trisulfide, lending credibility to the proposed mechanism.[I38J The use o f Lawesson’s 
reagent for the thionation o f dimethyl phosphite was reported by N. Zabirov and R. 
Shabana, with benzene and acetonitrile as the chosen solvents. Toluene was also 
believed to be a suitable solvent since it is closely related to benzene but m uch less 
carcinogenic. It was found that warming o f the reaction in toluene was necessary for 
complete solubility o f  Lawesson’s reagent, or the reaction would occur in low yields. 
Once completely dissolved, thionation o f dimethyl phosphite was nearly quantitative, 
however, failure to quench the reaction immediately resulted in overall yield reduction 
(Scheme. 5.1). DBQ staining was useful in monitoring the thionation reaction by TLC, 
as neither dimethyl phosphite nor dimethyl thiophosphite contain a strong enough 
chromophore to be UV active. 2,6-Dibromo-N-chloro-p-benzoquinoneimine (DBQ) 
reveals the presence o f a phosphorus-sulfur pi bond by producing a maroon colored spot 
after heating on TLC.
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B. Addition of DMTP to Imines Bearing Chiral Auxiliary Group
CH
CHSH
Addition to si faceAddition to re face
Figure 5.2. Diastereofacial addition o f dimethyl thiophosphite 
to an aldimine.
The strategy to the stereoselective addition o f dimethyl thiophosphite and 
dimethyl phosphite to the aldimines is to distinguish between the re and si faces o f the 
Schiff base (Fig 5.2). The synthesis o f the aldimines was conducted via the condensation 
o f the aldehyde (benzaldehyde, isobutyrlaldehyde, n-butyraldehyde, 
phenylacetylaldehyde, and 2-methylbutyrlaldehyde) with the amine containing a chiral 
auxiliary (phenyl glycinol, a-m ethyl benzyl amine, serine, and threonine methyl esters, 
Scheme. 5.2). The removal o f  water the reaction was necessary in order to drive the 
reaction to completion. TLC o f the product indicated that the starting material was 
consumed, however, the product Rf was inconclusive, as imines are known to hydrolyze 
upon contact with silica. It was found that the best way to monitor the reactions were by
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either LC MS+ or ’H NMR. Evaporation o f the solvent followed by Kugelror distillation
afforded the desired aldimines in acceptable purity as confirmed by the aldimine proton 
near 5 8.5 ppm.
The synthesis o f  dimethyl a-am ino thiophosphonate’s from dimethyl 
thiophosphite 57 was brought about via Pudovik methodology. The aldimine was 
dissolved in toluene and dimethyl phosphite was added via syringe and stirred at rt. The 
reaction was monitored by unlocked 3IP NMR and by TLC with the aid o f DBQ resulting 
in the production o f a maroon colored spot. When the reaction was complete the solvent 
was evaporated and the residual oil was then analyzed by 3IP NMR to calculate the 
diastereomer ratio o f  the reaction (Table 5.1, Fig.5.3). Silica chromatography o f the oil 
under refined conditions led to enantioenriched dimethyl a-am ino thiophosphonate 
diasteromers (Fig 5.4). All compounds were analyzed with 'H  (Fig 5.5) and l3C NMR.
106.3
MeO 
MeCL R - 0
Pv'
OH
103.6
10
■.w—rVfcJ J
Figure 5.3. Example o f 31P NM R spectra used to determine diastereomeric ratio of 
dimethyl thiophosphite or dimethyl phosphite addition.
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B
C
«w*»- .•U4- «*««r rfetessfe
Figure 5.4. 31P analysis o f the separation o f diastereomers with silica 
chromatography; [1], mixture o f two diastereomers [4] and [5], separated 
diastereomers after a silica column using 1% M eOH/CHCl3 as eluent.
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OH
B
MeO OH
Figure 5.5. A) 'H  spectrum o f [1 -(2-hydroxy- l-phenyl-ethylamino)-butyl]- 
phosphonothioic acid 0 ,0 -d im ethyl ester. B) Example o f  the posphorus 
methyl ester coupling.
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Table 5.1. Addition of dimethyl thiophosphite and dimethyl phosphite to imines
bearing a chiral auxiliary. Ratio’s were determined by 3IP NMR.
Inline Product % Yield 3iP Ratio
MeO 
MeO S L X  
P '-' =
J '■
■ I H H 
56, X  = S 57 . X =  0
A N
X=S, 63° o 
X = 0 , 48%
108.2/104.9
33.0/31.3
1 :0 .7  
1 :0.75
_ / C
-,u MeO 
m  M e O ^ I ^ S  , (
p  ^
i  J H H
58
DH
0
65% 106.3/103.6 1 :0.73
M g  0  v  
M eO ^
1 ? 1 ^
11 J  H H
59, X  = S 60. X  =  0
r .
X =S, 75%  
X = 0 . 63%
109 4 106 4
33.0/32.0
1 :0 .8
1 : 0.4
MeO
,Q H  M e O ^ U X  A
1 = 1 P "  "
^  I 1 .  1  =
H H
61, X = S 62, X  =  0
3H
0
X -S : 76%  
X = 0 , 46%
107.3/105.3
32.4/32.1
0.23 : 1 
1 :0.4
,OH MeO s  
V '  MeO ... l// .... OH 
!  P y  
...... A... .OMe I 1
0 /  " A  r N s V '
0
63
X=S. 62% 98.1/97.3 1 : 0.29
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Table 5.1. Addition of dimethyl thiophosphite and dimethyl phosphite to imines
bearing a chiral auxiliary. Ratio’s were determined by 31P NMR (continued).
Iinine Product % Yield '  ‘ P ppm Ratio
MeO 
MeO % I ^  X
i 'N '
H H
64, X=S 65. X = 0
X=S, 85% 
X =0 75%
108.2/104.9
32.7/31.6
1 :0 .47  
0 .9 :1
OH MeO M eO . U S  
P '
.OH
X=S. 73® 106.4 104.4 1 : 0.6
OH
""V
MeO 
M s 0  I S
x ,I N 
H H 
67
.OH
X = S .69% 100.5/98.1 1 :0 .32
' N '
MeO 
M e O .... S
P "
H H 
68
X=S. 5S% 101.7/99.0 1 ; 0.25
.OH
f
o
MeO
MeO „ U S  .OH% T..OMe | ?
69
OMe X=S.. 18% 98.1/97..: 1 : 0.38
O
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C. Asymmetric Dealkylation of Phosphorus Methyl Esters with PEX
The methodology for the synthesis o f enantioenriched dimethyl a-am ino 
thiophosphonic monoacids was based on the dealkylation o f less sterically hindered side 
o f the phosphonate diester with potassium ethyl xanthate (PEX). The hypothesis was that 
PEX would attack the less sterically confined ester carbon resulting in an asymmetric 
dealkylation to afford enantioenriched dimethyl a-am ino thiophosphonic monoacids (Fig. 
5.6, Table. 5.2). The dimethyl a-am ino thiophosphonate’s were dissolved in acetone and 
then PEX was added and stirred at rt until the reaction had completed. The progress was 
monitored by unlocked 3IP NMR by following the movement o f  peaks from 5 110-95 to 
around S 80 ppm for P=S and from 5 30-20 to S 20-10 for P = 0  (Fig. 5.7). Once the 
reaction had come to completion the monoacids were purified and analyzed by NMR 
(Fig. 5.8), then biologically tested as inhibitors o f thermolysin.
CH.
c h 3HO'
S'
Figure 5.6. PEX attacking the less stericdally hindered methyl ester.
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starting material
S i l £ ? S 3 S S a i f e
p ro d u c t
sta rting  m ateria l
Figure 5.7. 31P NM R monitoring th reaction progress o f the dealkylation of 
P=S and P = 0  with PEX.
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Table 5.2. Dealkylation of the phosphorus methyl ester with PEX.
Product %Yietd 31p  Ratio
MeO
HO,
P =
H J 
70
21% 74:6/72.3/71.6/68.2 1 0 : 8 : 7 : 5
MeO 
HO .. ; .-S
N T, '-A 
H
72
G
O
6'
'- 73.4/72,9 3:2
The compound 72, which was made from a single diasteromer, shows that 
asymmetric dealkylation is possible with PEX. Since only one diasteromer was used in 
the reaction you would expect a 1:1 ratio if  both methyl esters were sterically equivalent. 
Since the ratio is 2:3 there must be some steric bulk that is hindering PEX from attacking 
one of the methyl esters. Although the asymmetric dealkylation o f the phosphorus 
methyl ester was successful, there were some problems with the isolation o f compounds 
with a hydroxy functional group. The phosphonic acids with an auxiliary hydroxy group 
were all followed by 31P NMR and appeared to have a successful reaction, but when 
worked up the isolated products always had numerous 31P peaks in the spectrum, and
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none o f them correlated with the expected ppm shift. It is possible that upon purification 
the hydroxy group could act as a nucleophile and form a ring with phosphorus. 
Unfortunately the phosphorus acids proved to be extremely hard to purify due to its polar 
characteristics. Reverse phase chromatography was tried but was never very successful, 
the most efficient method was recrystalization with either ether or acetone, but this was 
still never successful with the hydroxy compounds.
D. Conclusions
The asymmetric addition o f DMTP and DMP to imines with a chiral auxiliary 
was successful. The diastereomer ratios ranged from poor (65) to good (63) and expected 
considering the high reactivity o f DMTP (as compared to DMP), distance from reaction 
center to asymmetric center, and weakly stereodifferentiating system topology.
Somewhat interesting was the finding that the hydroxy group present in the chiral 
auxiliary phenylglycinol had no additional effect relative to a-methylbenzylamine, 
whereas the presence/absence o f a hydroxy group on the amino acids did alter the 
diastereoselectivity. For example, changing the auxiliary from alanine to serine increased 
the ratio from 61:39 to 73:27. Conversely, the use o f threonine (branching at the 
hydroxyl group) as an auxiliary led to lowered diastereoselectivity possibly as the result 
o f steric and conformational limitations. Attempts to use cysteine methyl ester as 
auxiliary to examine the role o f a sulfhydryl was conducted however the reaction with 
benzaldehyde forms the tetrahydrothiazole prior to imine formation.
It is worthy to note that the addition o f DMTP was about 1000 fold faster than the 
addition o f DMP. The faster rate o f DMTP made it possible to make the APTA
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precursors with imines that were not stable for a long period o f time plus enhancing 
asymmetric addition. In the case o f  DMP only imines that were stable for days could be 
used in the reaction due to amount o f time required for the reaction to come to 
completion. All o f the DMTP and DMP addition products were stable for days at room 
temperature but the DMTP adducts had to be kept under Ar(g) to prevent oxidation. The 
separation o f diastereomers was achieved on some the compounds, but a more thorough 
study could be with separation with chiral HPLC columns. The asymmetric dealkylation 
was accomplished with PEX on all o f the precursors but isolation was difficult with the 
auxiliary hydroxy compounds due to side reactions during the work up resulting in 
numerous products. It is worthy to note that the use o f a chiral dealkylating agent may 
enhance the asymmetric dealkylation o f the precursors.
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Chapter 6
Preliminary Assay of a-Aminophosphonothioic Acid as Thermolysin Inhibitors 
A. Kinetics
Kinetics are concerned with the rates o f reactions. This is a very important matter 
for the body which maintains its steady state by adjusting reaction rates in response to the 
environment and to hormonal controlsJ139̂ Chemical reactions are classified according to 
the number o f reactants. In the simplest case, the first order reaction, there is just one 
reactant and the rate o f  the reaction is proportional to the concentration o f  that reactant. 
Hence, a graph o f reaction rate against reactant concentration is a straight line for a first 
order chemical reaction (Fig 6.1).[ 1401
Reaction 
Rate. V
C oncentration of A. [A]
Figure 6.1. First Order Chemical Reaction, V vs. [A],
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In the case o f  enzyme-catalyzed reactions the kinetics are not so simple except under 
carefully chosen conditions. The course o f an enzyme-catalyzed reaction is generally 
complex and enzyme reactions are usually characterized by measuring the initial rate of 
the reaction, Vo, which is the reaction rate at time equal to zero. In a closed system, such 
as a test-tube, an enzyme reaction can be started by adding the enzyme to a solution of 
the substrate and other compounds that are required for the reaction. The reaction will 
start at a high rate and slow down over time for several reasons: ( 1 ) the substrate will be 
used up and so the reaction rate will slow down as each enzyme molecule spends more 
time diffusing through the solution before it collides with a new substrate molecule, (2 ) 
as the reaction proceeds, product will accumulate and this may tend to inhibit the 
enzyme, (3) the enzyme molecules may gradually lose activity due to random hydrolysis 
or denaturation.[l40J
To simplify the kinetics, we will start by considering only the reaction rate right at 
the beginning o f the reaction, so that we do not have to worry about the three points 
previously noted are not o f concern. The reaction rate at time 0, Vo is the initial slope of 
the graph o f  product concentration against time (Fig. 6.2). Vo can be measured for a 
variety o f initial substrate concentrations, in order to understand how the reaction rate 
will change in response to changes in substrate concentration. At very low substrate 
concentrations, a graph o f reaction velocity (v) against substrate concentration will be a 
straight line, like the first order chemical reaction. However, for an enzyme-catalyzed 
reaction, even with only one substrate and one product, this graph will curve at higher 
substrate concentrations and will level off at very high substrate concentration . ^ 40’ 1411
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Product
Concentration
Tone
Figure 6.2. Time Course for Enzyme Reaction
In other words: when the substrate is at a low concentration, it is the limiting factor and 
so an increase in substrate concentration produces a proportional increase in reaction rate. 
However, as the substrate concentration increases, the enzyme concentration becomes the 
limiting factor and then a further increase in substrate produces a less-than-proportional 
increase in reaction rate. Eventually, the enzyme becomes “saturated” and the reaction 
rate reaches a constant value that does not increase significantly as yet more substrate is 
added. The maximum reaction rate that is achieved is called the V max.
If  the enzyme concentration is then increased, the Vmax will increase because there are 
more enzyme molecules available to carry out the reaction. The V maX > therefore, is only 
proportional to the enzyme concentration (i.e. Vmax = kcat x [E] where Kcat is a constant).
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The equation used to describe the time course o f  an enzyme reaction is called the
Michaelis-Menten equation:
v _  [S]
K * + [S 1
where v = rate o f the enzyme
Vmax = kcat x [E] and [E] = enzyme concentration
K m = '/2 Vmax
[S] = substrate concentration
The Michaelis-M enten equation can be derived from the chemical kinetics o f a very 
simplified enzyme reaction with the assumption that there is only one intermediate state, 
the enzyme-substrate complex (ES). Since we are dealing with initial velocities it is not 
necessary to consider the back reaction . [ l41 ] Thus, the chemical equation for an enzyme 
catalyzed reaction is:
Kcat is the turnover number o f the enzyme. The turnover number is the number of 
substrate molecules converted into product per active site at very high substrate 
concentration. The velocity o f an enzyme reaction increases as [S] increases. When [S] 
becomes much larger than Km the velocity approaches a constant, i.e., as [S]—>°o,
Vo—>Vmax. Hence, Vmax is the maximum velocity that can be achieved with a given total 
enzyme concentration and it can be measured as the limiting velocity obtained as [S] is 
increased. Since the theory shows that Vmax = kcat [E] where [E] is the total enzyme
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concentration, the V max is proportional to enzyme concentration. Thus kcat is a property 
o f the enzyme and its substrate and, unlike Vmax, is independent o f enzyme 
concentration. The Vmax o f an enzyme is a measure o f how fast the reaction it catalyzes 
can proceed once the enzyme-substrate complex is formed.
K m is the Michaelis-Menten constant and represents the substrate concentration 
that produces half the maximum velocity (Fig. 6.3). Therefore if  K m is large, the whole 
curve is towards the right and the reaction rate at low substrate concentration is very low 
Alternatively, if  the K m is small, the curve is towards the left and the reaction rate at low 
substrate concentration is relatively high. If  K m and kcat are known for a given enzyme, 
we can use the Michaelis-Menten equation to calculate the reaction rate, Vq.
max
K■m
Figure 6.3. K,„ defined on a graph.
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The M ichaelis-M enten equation can be converted to a linear form by plotting 
1/Vo against 1/[S] and the result is called a double reciprocal plot or a 
Lineweaver-Burk plot (Fig 6.4). The plot can be used to evaluate KOT/V max and 1/Vmax 
from the slope and y-intercept. The equation is:
i _ i  , j
^  m ax [S]
The fact that the “curve” is a straight line is a useful indicator that the Michaelis-Menten 
equation does actually describe the kinetics o f the enzyme under study.
4
9
max
i
i
K m K_, v
-k --------
[S]
Figure 6.4. A Lineweaver-Burk plot o f 1/v vs. 1/[S]. The intercept on the 
y-axis is equal to 1/Vmax and the slope is equal to K,„/Vmax.
102
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
An alternative o f the Michaelis-Menten equation occurs when v/[S] vs. v is 
plotted, which is called the Eadie-Hofstee plot (Fig. 6.5). It is fitted by the equation:
max
The slope o f the graph is -1/K„„ the intercept on the v/[S] axis is Vmax/K m, and on the v 
axis it is V max-
m
2 K m
—  v•I * max
V
Figure 6.5. The Eadie-Hofstee plot o f v/[S] vs. v. The 
slope is -1/K,„, the intercept on the y-axis is V max/K m, and 
the intercept on the x-axis is V max.
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The Lineweaver-Burk plot is useful for distinguishing between types o f inhibition. The 
Eadie-Hofstee plot is better than the Lineweaver-Burk plot at picking up deviations from 
the Michaelis-M enten equation.
B. Competitive Inhibition
If  a reversible inhibitor can bind to the enzyme active site in place o f  the 
substrate, it is described as a "competitive inhibitor." In pure competitive inhibition, the 
inhibitor is assumed to bind to the free enzyme but not to the enzyme-substrate (ES) 
complex . [l401 The binding is described as shown below:
Here Kj is the dissociation constant for the enzyme inhibitor-complex (El). Using the 
steady state theory and writing a mass balance equation that includes El along with the 
enzyme and ES, an equation relating rate to substrate concentration that is analogous to 
the Michaelis-Menten is obtained. However K m is replaced by an apparent K m’ 
defined as:
E + S ES
E |
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El does not react to form E + P, and the enzyme is unable to bind both S and I at the same 
time. The Michaelis-Menten, Lineweaver-Burk, and Eadie-Hofstee equations can all be 
modified to include a term that describes the inhibition by I when substituting Km’ for 
K m
A common test for competitive inhibition is to use the refined Lineweaver-Burk 
and Eadie-Hofstee equations in the absence o f inhibitor and in the presence o f  one or 
more fixed concentration o f I. The result is a series o f lines that converge on one o f the 
axes at the value o f 1/Vmax. Since the inhibitor only the effects the formation o f the ES 
complex and the not the conversion o f ES to E+P, the maximum velocity is unchanged 
by the presence o f the inhibitor.^141!
C. Thermolysin Photometric Assay
A number o f furylacryloyl dipeptide substrates (Fig. 6 .6 ) for the neutral proteases 
have been prepared which permit the dipeptide hydrolysis to be monitored 
spectrophotometrically.^142̂ The study o f  thermolysin-catalyzed hydrolysis o f these 
substrates has yielded kinetic information o f this enzyme(kcat/K m = 2.11). The substrate
3-(2-furylacryloyl)-glycyl-L-leucine amide (FAGLA) is cleaved by thermolysin by 
hydrolyzing the glycine-leucine bond (Fig. 6 .6 ). FAGLA’s advantage is that thermolysin 
can cleave it in only one place (as shown in Figure 1), making the reaction specific 
enough that the decrease o f substrate could be easily quantified by measuring the
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o
N/ 'v ]j^  NH2 Thermolysin^ ®
X = 345nm
Figure 6.6. Thermolysin catalyzed proteolytic cleavage o f N-(3-[2- 
furyl]acryloyl)-glycyl-L-leucine-amide (FAGLA).
decrease in optical density at X = 345nm. The activity (both inhibited and uninhibited) o f 
thermolysin can thus be determined using UV- Visible spectrophotometric analysis . [1431 
In other words, when the enzyme is not inhibited FAGLA is cleaved by the active site 
and a decrease in absorbance at 345nm is observed, but when the enzyme is inhibited, 
FAGLA can not be cleaved by the active site and the absorbance at 345nm stays constant 
(Fig. 6.7).
Since the original assay was designed to be carried out in 1 cm cuvettes the 
procedure was modified for a micro plate reader in order to gain a higher throughput. 
When the experiment was changed from a 1 cm cuvette to the micro well plate reader a 
drop in sensitivity o f the assay became apparent. The assay still worked for strong 
inhibitors o f  thermolysin, like phosphoramidon, but not for weak inhibitors, so the assay 
was used as a screen for the panel o f compounds made in the Thompson lab. The data 
was collected and analyzed using the software Soft Max Pro and interpreted in Excel (Fig 
6 .8 , Table 6.1)
106
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Time (secs)
Vmax Pdnls = 61 
Weil o  E3
Vmax -7.340 A
1*2 0 9 9 8
0.9-
0 .8 -  — ......
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0.4-
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0.1 - •
- 0.1
500400 60015Q 200 250 3001Q0500
Time (secs)
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V max -2 4 0 5
f*2 0.970
Figure 6.7. UV monitoring of thermolysin substrates using FAGLA by 
observing absorbance at 345nm using a micro plate reader and Soft max pro. 
A) thermolysin uninhibited (decrease in 345 nm). B) thermolysin inhibited 
by 70 (345nm stays constant).
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Trial 1
Sample [ s i ........... [S] corr. 1 /[S]  ’ v :v corr. 1/v [Ej kcap/Km v / lS ]
2E-03 1.S5E-03 5.17E-04 .71.935 - 4.90 # # # # # #  -1 2 2 4 4 .9 3.07E-08 -9.48E+03
2E-04 1.55E 04 S.17E-05 19354 - 0I9 0 7 4 4 # # # #  -6 6 6 6 6 .7 3.07E-08 -9 .47E +06 -1.74E+04
3E-04 2 .33E -04 7.76E-05 12884 -1.10! # # #■ ###  -S4S4S.5 3.07E-0S -7.70E+-06 -1 .42E+04
5E-Q4 3.1OE-04 1.03E-04 9677 -1.70! # # # # # 4  - 35294 .1 3 .07E-08 -8 .9 4 5 + 0 6 - 1.65E+04
7E-04 4.65E- 04 l .SSE -04 7 6451 -2 .30  # # # 4 4 4  -26087 .0 3.07E-08 -8 .06E +06 - 1.48E+04
Average -8 .54E +06
Std Dev S.06E+05
Slope -3 .26409: r-A 2 v=(kcat/Km)fE]rTl
Y int. -61 2 9 .3 2 0 .97136 v/[S3 = (Vmax/Km) - v * (1/Km)
Vmax -0 .0 0 0 1 6
Ave Km 3.3SE-04
Bl/Ki 0 .588 Ave kcat/Km= -5 .33E +06
10............ 1.47E-06 stdev  kcat/Km= 4.65E+06
Ki 2.50E-C6 Ave Ki- 4 .35E -06
kcat l 2 ;8 7 i+ 0 3
Trial 2 ...
Sample 1ST £S] corr. . l /C S ] ’ v v corr. 1 /v [ E f ....... kcap'Km v / r s ]7
2E-03 1.55E- 03 S.17E-04 1935 - 4 .2 0 ! # # # # # #  -1 4 2 8 5 .7 3.07E-08 -8.13E+03
2E-04 1.55E-Q4 S.17E-05 19354
3E-04 2.33E-04 7 .7 6 E 0 5 12884
SE-04- 3.10E-04 1.03E-04 9677 -1 .5 0  # # # # # #  - 40 000.0 3.07E-08 -7 .89E +06 - 1.45E+04
7E-C4 4 .65E -04 1.5SF-04 6451 :2i00! # # # # # #  ; -3 0 0 0 0 .0 3.07E-0S -7 .01E +06 - 1.29E+04
Average -7 .4SE+06
Std Dev 6.20E+05
Slope -3 .3 3 1 7 1 rA2 ..7 .1.
Y int -80 3 4 .0 8 0 .999
Vmax -1.24E 04
Ave Km 3.35E -04
[13/Ki 0 .236
[I]...... 1.47E-06
Ki 6 .20E-06
kcat -2 .50E+03
Figure 6.8. Data imported into Excel from Soft Max Pro and put into the Eadie- 
Hofstee equation to help calculate average K; o f 70.
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Table 6.1. Kj values o f substrates tested on thermolysin using 
FAGLA and a micorwell plate reader
Substrate K { (mM)
MeO 
HO.„ S 
P "  z
' ’’"‘- r 'T ' ' '  n a
H H 1
'"-'-A'''
4.28
. A
MeO 
HO,, ^ , S1 p _
^  G N 4 
H H
1.69
MeO 
HO,, > .,-0  
P'- r
LA A^  i N' ■ 
H H
{•''"A ;
A.
4.18
Although the results did not show substantial inhibition o f thermolysin they did 
show partial inhibition. This was not to much o f  a surprise since the compounds tested 
did not have carboxylic acid functional group which has been proven to help guide the 
peptide into the active site. But the preliminary results show that there is some 
coordination to the active site suggesting that the P=S and P = 0  can coordinate with the
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zinc atom within the site. To help bind the inhibitor an additional peptides may be added 
in order to fill more S pockets o f the enzyme. Plus, resolving the diastereomers and 
testing them separate would most likely lead to a higher inhibition since the substrates 
would not be competing with its diastereomer for the active site.
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Chapter 7
Conclusions 
A. Synthesis and Testing of APTA Compounds
In conclusion, DMTP adds with good diastereoselectivity to imines containing N- 
chiral auxiliaries. Using readily available chiral amines, a-aminophosphonothionates 
may be prepared in good yield and high stereoselectivity. Using these findings, the 
synthesis o f A PTA ’s containing a P-chiral group will be possible. The asymmetric 
dealkylation o f  the phosporus methyl esters was accomplished with PEX, but the use o f a 
chiral nucleophile may emphasize asymmetric attack by capitalizing on the sterics o f the 
methyl ester and should be explored.
Adapting the thermolysin assay for the micro plate reader was accomplished, but 
it only showed strong inhibition and can only be used for preliminary results. The main 
problem with the assay was the background noise was often to high and would make the 
subtle drop in absorbance difficult to quantify. W ork is being done on developing a MS 
assay using single ion monitoring and should prove to be a better assay.
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Chapter 8
Future Work 
A. Building a Tripeptide Mimic
Since the S and S’ pockets of ACE have been elucidated it is known that there are 
three primary sites that guide and hold the peptide in the active site. It would then seem 
prudent to match a peptide for each pocket o f the enzyme. In other words, if  there are 
three subsites in the enzyme than the inhibitor should have three peptides to fully exploit 
its inhibitive properties. Thus, the dipeptides that have been made in this study could be 
improved with the addition o f another peptide.
Initial attempts to functionalize the hydroxyl group o f the a -  
aminophsphonothioates with phenyl glycinol, serine methyl ester, and threonine methyl 
ester (63, 67, and 69) were unsuccessful but had interesting results. The Mitsunobu 
reaction with triphenylphosphine and diethyl azodicarboxylate resulted in the oxidation 
o f the hydroxy unit to an aldehyde. Although it was not the expected outcome, the 
aldehyde could provide some interesting synthetic routes. Following dealkylation o f the 
phosphorus ester an imine could be made which could be attacked by sulfur to form a 
mechanistic transition state adduct (Fig. 7.1).
A third amino acid could also be coupled with the phosphonic monoacid via a 
DCC coupling reaction. Once the tripetide is made by the coupling o f an amine with the 
phosphonic acid a second dealkylation would provide a TS analog that has the zinc 
binding group incorporated into the peptide framework which would mimic the
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angiotensin enzyme more closely than the dipeptide with the zinc binding group in the 
terminal position (Fig 7.2).
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Figure 7.1. Mitsunobu reaction and possible route to mechanistic 
transition state inhibitor.
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Figure 7.2. APT A coupling with DCC and an amine followed by dealkylation 
with PEX to afford a tripeptide transition state inhibitor.
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Chapter 9
Experimental 
A. iso-Polydiacetylene Compounds
Unless otherwise noted, reactions were run in flame-dried apparatus under argon 
atmosphere. Anhydrous reagent grade solvents (CH2CI2; THF; toluene; CH3OH; 
benzene) were purchased from Aldrich Chemical Co. in sure sealed bottles and used 
without further purification. Protected amino acids, phenyl glycinol, a - 
methylbenzylamine, isobutyryl chloride, isobutyryl aldehyde, cyclohexanecarbonyl 
chloride, trimethyl phosphite, 3-methyl-butyraldehyde, phenyl-acetaldehyde, Pd(PPfi3), 
Cul, TEA, diisopropyl ethyl amine, t-butyl alcohol, and lawesson’s reagent were 
purchased from Aldrich Chemical Co. and used without further purification, bis- 
Trimethylsilyl acetylene was purchased from Petrarch and used without further 
purification. Analytical thin-layer chromatography (TLC) was performed on silica gel 
(Whatman) aluminum-backed plates. Flash chromatography was performed with silica 
gel (Merck, 230-240 mesh). Compounds were detected using a UV lamp at 254 nm 
and/or stained with ninhydrin or 2,6-dibromoquinone-chlorimide. Yields are optimized. 
'H  NMR (400 MHz), 13C NMR (100 MHz), 31P NMR (171 MHz) spectra were 
determined on a Varian 400 MHz Unity Plus spectrometer. Chemical shifts are reported 
in parts per million (ppm, 5) using CHCI3 (7.26 ppm for 'H), CDCI3 (77 ppm for 13C) or 
85% H3PO4 (0 ppm for 3 IP). as references. High resolution mass spectra (HRMS) were 
obtained using electrospray ionization (ESI) Micromass LCT connected with water 2790
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HPLC with C-18 reversed phase column (2.1 mm i.d., 5 cm long). Elemental analyses 
for C, H, and N were performed by Midwest Microlab, Indianapolis, IN. All the HRMS 
and elemental analyses o f the novel compounds are within acceptable error range.
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B. compounds 22-45
CHC1-
0  -€
l-Trim ethylsilanyl-4-methyl-pent-l-yn-3-one (22). In a flask was placed CH2CI2 (100 
mL), bis(trimethylsilyl)acetylene (10.24 g; 60.0 mmol), and isobutyryl chloride (6.36 g; 
60.0 mmol) and reduced temperature to 0 EC with an acetone/ice bath. To this was 
added AICI3 (8.00 g; 60.0 mmol) and let contents stir at ambient temperature for 6.0 h. 
The reaction changed from a cloudy opaque color to a cloudy dark amber. The reaction 
was then concentrated in vacuo resulting in a dark red oil. The oil was diluted with 
EtOAc (50 mL) and then poured into a beaker with ice-cold 10% EIC1 (150 mL) 
transmuting the dark amber color to bright yellow. The reaction was extracted with 
EtOAc (3x100 mL) followed by extraction of the organic phase with H2O, sat. N aH C 03, 
and brine. The organic phase was then dried over anhydrous N a2SC>4 for 0.5 h and 
concentrated in vacuo resulting in dark red oil. Compound 22 (8.98 g; 53.4 mmol; 89 %) 
was isolated as a colorless oil after distillation at 43 EC at 0.25 mmHg.
'H N M R (C D C 13, 400 MHz): 5 2.50-2.57 (m, J  = 7.1 Hz, 1H), 1.09 (d, 7 =  7.1 Hz, 6  H), 
0.15 (s, 9H);
,3C NMR (CDCI3, 100 MHz): 5 192.6, 102.0, 99.5, 43.7, 18.8, 0.2.
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CHC1-
l-cyclohexyl-3-trimethyIsiIanyI-propyn-l-one (31). To a flask was added CH 2CI2 (100 
mL), bis(trimethylsilyl)acetylene (5.12 g; 30.0 mmol), and cyclohexanecarboxylic acid 
chloride (4.39 g; 30.0 mmol). The temperature was brought to 0 EC with an acetone/ice 
bath, and AICI3 (4.00 g; 30.0 mmol) was added and let stir at ambient temperature for 6 . 0  
h. The reaction mixture changed from a cloudy opaque color to a cloudy dark amber 
during this period. The reaction mixture was then concentrated in vacuo resulting in a 
dark red oil. The oil was diluted with EtOAc (50 mL) and poured into a beaker that 
contained iced 10% HC1 (150 mL) transmuting the dark amber color to bright yellow.
The reaction mixture was separated, extracted with EtOAc (3x100 mL) followed by 
extraction o f the organic phase with H2O, sat. NaHCCL, and brine. The organic phase 
was then dried over anhydrous Na2S0 4  for 0.5 h and then concentrated in vacuo resulting 
in dark red oil. Compound 31 (3.88 g; 18.62 mmol; 62 %) was isolated as a colorless oil 
after distillation at 76 EC at 0.25 mmHg. Anal. Calcd for: C ^H ^O Si: C, 71.24; H,
6.97; Found: C, 71.04; H, 7.01.
'H  NMR (CDCI3, 400 MHz): 5 2.36-2.48 (m, J =  3.8 Hz, 1 H), 2.00-1.96 ( m , J =  3.8 Hz, 
2 H), 1.81-1.77 ( m , J =  3.8 Hz, 2 H), 1.68-1.65 (m, J =  3.8 Hz, 1 H), 1.46-1.19 (m, J  = 
3.8 Hz, 5H ), 0.18 (s, 9 H);
13C N M R  (CDCI3, 100 MHz): 8  192.4, 102.5 ,99 .5 ,53 .1 ,29 .2 , 26 .8 ,26 .4 ,0 .4 .
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2-methyl-l-trimethylsilanylethynyl-propenyl trifluoromethanesulfonate (32). To a
100 ml RB flask was added CH2C12 (50 mL), 2,6-di-tert-butyl-4-methylpyridine (1.33 g; 
6.5 mmol), and 22 (1.00 g; 6.0 mmol). It was then cooled to -7 8  EC under Ar (g). 
Triflouromethane sulfonic acid (2.01 g; 7.20 mmol) was added via syringe and then the 
reaction was warmed to rt while stirring. After 8.0 h the reaction had turned to a dark 
brown color and was concentrated in vacuo resulting in a chunky brown salt. Pentane 
(100 mL) was added to the brown precipitate and the insoluble triflate/2,6-di-tert-butyl-4- 
methylpyridine salt was gravity filtered. The brown organic layer was then extracted 
with iced 10% HC1, H 20 , sat. N aH C 03, brine, and dried over N a2SC>4 . The solution was 
then concentrated in vacuo to afford dark brown oil. The oil was distilled at 0.25 mmHg 
and 65 EC resulting in a clear colorless oil (1.41 g; 4.69 mmol; 78%).
'H  NMR (CDC13, 400 MHz): 5 1.98 (s, 3 H), 1.91 (s, 3 H), 0.21 (s, 9 H);
13C NM R(CDC13, 100 MHz): 5 138.6, 127.7, 119.0(q, J =  320 Hz), 101.2,95.5,22.1,
19.6,0.48.
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l-Cyclohexylidene-3-trimethylsilanyl-prop-2-ynyl trifluoromethanesulfonate (33).
l-cyclohexyl-3-trimethylsilanyl-propyn-l-one (5.41 g; 26.0 mmol) and 2,6-di-/erf-butyl-
4-methylpyridine (6.42 g; 31.3 mmol) in CH2CI2 (225 mL) was chilled to -7 8  EC and 
triflouromethane sulfonic acid (8.62 g; 5.14 ml; 30.5 mmol,) was added dropwise via 
syringe. The reaction was warmed to rt after 0.5 h and at 8.0 h the reaction had turned to 
a dark brown color. The reaction concentrated in vacuo resulting in a chunky brown 
solid. Pentane (100 mL) was added to the brown precipitate and the insoluble triflate/2,6- 
di-tert-butyl-4-methylpyridine salt was gravity filtered. The brown organic layer was 
then extracted with iced 10% HC1, H20 , sat. NaHCCL, brine, and dried over Na2S0 4 . 
Evaporation in vacuo followed by flash chromatography with hexanes gave 33 as clear 
yellow oil (6.55 g; 19.2 mmol; 74%).
'H  NMR (CDCI3, 400 MHz): 5 2.42-2.34 (m, J =  6.3 Hz, 4 H), 1.68-1.58 (m, J=  6.3 Hz, 
6  H), 0.21 (s, 9H );
I3CN M R (C D C13, 100 MHz): 6  146.1, 127.7, 119.0 (q, J =  320 Hz), 101.2, 95.5,31.2,
28.6,27.0, 26.6,25.7, 0.48.
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0 .0 1M Borax
MeOH, rt
l-cycIohexyl-2-propyn-l-one (34). To a 100 mL RB flask was added MeOH (35 mL), 
0.01 M Borax (3.9 mL), and l-cyclohexyl-3-trimethylsilanyl-propyn-l-one (500 mg, 2.40 
mmol). The reaction was stirred at rt for 12 h and the mixture changed from colorless to 
pale yellow. The reaction was then quenched at 0 EC with iced 10% HC1 (50 mL). The 
solution was extracted with hexanes (3 x 30 mL). The organic layers were combined and 
extracted with sat. NaHC0 3  and dried over Na2S0 4  for 15 min. The organic layer was 
then filtered and concentrated in vacuo to afford a crude yellow oil. The yellow oil was 
then distilled at 0.25 mmHg and 49 EC to afford 34 (0.286 ;, 2.10 mmol ; 87%). Anal. 
Calcd for: C 9H 12O: C, 79.37; H, 8 .8 8 ; Found: C, 79.45; H, 8.64.
'H  NMR (CDCb, 400 MHz): 6  3.23 (s, 1 H), 2.36-2.48 (m, J  = 3.8 Hz, 1 H), 1.99-1.95 
(m, .7 = 3.8 Hz, 2 H), 1.78-1.75 (m, J  = 3.8 Hz, 2 H), 1.65-1.63 (m, ,7 = 3.8 Hz, 1 H), 
1.45-1.14 (m, J  = 3.8 Hz, 5 H);
13C NMR (CDCI3, 100 MHz): 8  191.7, 80.7, 78.9, 52.1, 27.8, 25.6, 25.2.
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Pd(PPh3)4, Cul
l-CycIohexyl-4-isopropylidene-6-trimethylsilyl-2,5-hexyne-l-one (35). To a 100 mL
RB 3 neck flask containing anhydrous benzene (15 mL), 32 (2.00 g; 6.64 mmol), Hunig’s 
base (2.52 g; 2.4 mL; 9.92 mmol), Pd(PPh3)4 (168 mg; 0.14 mmol, 2.2 mol%), and Cul 
( 6  mg; 0.0026 mmol) was degassed with Ar (g) for 0.75 h. To this solution was added, 
via syringe pump at 0.01 mL/min, 34 (1.32 g; 9.71 mmol) dissolved in anhydrous 
benzene (3 mL). When the addition was complete the reaction was diluted with 
Et2 0 :Hex (1:1) (100 mL) and then extracted with 10% aqueous HC1. The combined 
aqueous layers were back extracted with Et2 0 :Hex (1:1) (2 x 30 mL) followed by 
extraction o f the organic layer with H2O, aqueous NaHCCL, brine, and dried over MgSCfl 
for 0.5 h. The solution was gravity filtered and concentrated in vacuo to afford dark 
brown oil. 35 (1.084 g; 3.86 mmol, 58%) was isolated after flash chromatography with 
silica and 0.3% EtOAc/hex (5 L) as yellow oil. Anal. Calcd for: C igH^OSi: C, 75.46; H, 
9.15; Found: C, 75.51; H, 9.03.
'H  NMR (CDCI3, 400 MHz): 5 2.39-2.46 (m, J  = 3.9 Hz, 1 H), 2.08 (s, 3 H), 2.06 (s, 3 
H), 2.00-1.96 (m, J  = 3.2 Hz, 2 H), 1.79-1.74 (m, J  = 3.9 Hz, 2 H), 1.65-1.61 (m, J  = 3.9 
Hz, 1 H), 1.49-1.14 (m, J  = 3.2 Hz, 5 H) 0.19 (s, 9 H);
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13C NM R (CDCI3, 100 MHz): 5 192.4, 163.5, 101.4, 100.8, 98.8, 90.6, 89.7, 53.4, 29.4,
26.9, 26.5,24.4, 24.3,0.9.
123
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
TMS/OTf
TMSO OTMS
-78 °C
2-m ethyl-3-[l,3]dixolane-l-trim ethylsilyl-l-pentyne (36). To a 100 mL RB flask was 
added CH2CI2 (25 mL) and trimethylsilyl trifluoromethanesulfonate (11.3 mg; 9.0 pL; 
0.05 mmol) at -7 8  EC. To this solution was added l,2-bis(trimethylsilyloxy)ethane (1.05 
g; 1.25 mL; 5.10 mmol) and 4-methyl-l-trim ethylsilanyl-pent-l-yn-3-one (0.840 g; 5.00 
mmol) and stirred at -78  EC for 1.0 h. The reaction was warmed to rt and after 13 h the 
color had changed from colorless to a dark amber. Anhydrous pyridine (5.0 pL) was 
added via syringe and then stirred for 1.0 h. The reaction was then transferred to a 
seperatory funnel and extracted with aqueous Na2SC>4 and CH2C12 (3 x 40 mL). The 
organic layers were combined and dried over Na2S0 4  followed by evaporation in vacuo 
to afford dark amber oil. The oil was distilled to yield 36 (0.917 g; 4.32 mmol, 87%). 
Anal. Calcd for: C n H 2o0 2Si: C, 62.21; H, 9.49; Found: C, 62.03; H, 9.33.
'H  NMR (CDCI3, 400 MHz): 5 4.12-4.09 (m, J=  3.8 Hz, 2 H), 3.99-3.96 (m, J =  3.8 Hz, 
2 H), 1.99 (m, J =  6.4 H z,l H), 1.06 (d, J =  6.4 Hz, 6  H), 0.18 (s, 9 H);
13C NMR (CDCI3, 100 MHz): 5 107.4, 102.7, 90.2, 65.9, 37.6, 18.2, 0.9.
124
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
0
r A
TMS/OTf O. .0r a
TMSO OTMS
TMS CH2CI2 
-78 °C
TMS
l-cyclohexyI-l-[l,3]dioxolane-3-trim ethylsiIyl-2propyn-l-one (37). A 100 ml RB
flask, purged with Ar(g), containing CH2CI2 (25 mL) and trimethylsilyl 
trifluoromethanesulfonate (11.3 mg; 9.0 pL; 0.05 mmol) was cooled down to -78  EC.
To this solution was added l,2-bis(trimethylsilyloxy)ethane (1.05 g; 1.25 mL; 5.10 
mmol) and 4-m ethyl-l-trim ethylsilanyl-pent-l-yn-3-one (1.04 g; 5.00 mmol) and stirred 
at -78  EC for 1 h. The reaction was warmed to rt and after 13 h the color had changed 
from colorless to a dark amber. Anhydrous pyridine (5.0 pL) was added via syringe and 
then stirred for 1 h. The reaction was then transferred to a seperatory funnel and 
extracted with aqueous Na2S 0 4 and CH2CI2 (3 x 40 mL). The organic layers were 
combined and dried over Na2S0 4  followed by evaporation in vacuo to afford dark amber 
oil. The oil was distilled to yield 37 ( 8 6 6  mg; 3.43 mmol, 6 8 %). Anal. Calcd for: 
C ,4H2 4 0 2Si: C, 66.61; H, 9.58 C, 66.61; H, 9.58; Found: C, 66.05; H, 9.52.
'H  NMR (CDCI3, 400 MHz): 6  4.12-4.08 (m, J =  3.8 Hz, 2 H), 3.96-3.92 (m, 7 = 3 .8  Hz, 
2 H), 2.10-1.21 (m, 11 H), 0.18 (s, 9 H);
13C NMR (CDCfl, 100 MHz): 6  106.6, 103.1, 90.3, 65.7, 47.1, 28.2, 27.3, 26.9, 0.9.
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MeOH
2-m ethyl-3-[l,3]dixolane-l-pentyne (38). To a 100 mL RB flask was added 35 ml 
MeOH (35 mL), K2CO3 (1.0 g, 7.23 mmol), and 37 (500 mg, 2.35 mmol). The reaction 
was stirred at rt for 2.0 h where the solution changed from colorless to pale yellow. The 
reaction was then quenched at 0 EC with iced 10% HC1 (50 mL). The solution was 
extracted with hexanes (3 x 30 mL). The organic layers were combined and extracted 
with sat. N aHC 0 3  and dried over Na2S0 4  for 15 min. The organic layer was then filtered 
and concentrated in vacuo to afford a crude yellow oil that had the smell o f pine. The 
yellow oil was then distilled at 0.25 mmHg at rt to afford 38 (0.275 g, 1.95 mmol ; 83%).
'H  NMR (CDCI3, 400 MHz): 5 4.12-4.09 (m, 7  = 3.8 Hz, 2 H), 3.99-3.96 (m, 7  = 3.8 Hz, 
2 H ) ,2.51 (s, 1 H), 1.95 (m, 7 = 6 .4  H z,l H), 1.06 (d ,7 = 6 .4  Hz, 6  H);
13C NMR (CDCI3, 100 MHz): 5 106.6, 102.1, 82.2, 65.0, 36.6, 18.4.
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Pd(PPh3)4 r ~ \
r a Ov n
n n OTf TEA
Cul
•TMS
H
TMS
2-M ethyl6-cyclohexylidene-3-[l,3]dioxane-2-M ethyI-6-trimethylsilyl-4,7-heptyne 
(39. )To a 100 mL RB 3 neck flask containing anhydrous benzene (15 mL), 33 (2.00 g; 
5.87 mmol), TEA (0.89 g; 1.23 mL; 8.77 mmol), Pd(PPh3) 4 (148 mg; 0.12 mmol, 2.2 
mol%), and Cul ( 6  mg; 0.0026 mmol) was degassed with Ar (g) for 0.75 h. To this 
solution was added, via syringe pump at 0.01 mL/min, 38 (1.20 g; 8.58 mmol) dissolved 
in anhydrous benzene (3 mL). When the addition was complete the reaction was diluted 
with Et2 0 :Hex (1:1) (100 mL) and then extracted with 10% aqueous HC1. The combined 
aqueous layers were back extracted with Et2 0 :Hex (1:1) (2 x 30 mL) followed by 
extraction o f  the organic layer with EI2O, aqueous N aH C 03, brine, and dried over M gS0 4 
for 0.5 h. The solution was gravity filtered and concentrated in vcicuo to afford dark 
brown oil. 39 (0.87 g; 2.64 mmol, 45%) was isolated after flash chromatography with 
silica and 0.3% EtOAc/hex (3 L) as yellow oil.
'H  NMR (CDCfj, 400 MHz): 8  4.11-4.09 (m, J  = 3.8 Hz, 2 H), 3.98-3.97 (m, J  = 3.8 Hz, 
2 H), 2.02-1.98 (m ,J =  3.8 Hz, 4 H), 1.96-1.93 (m, J =  6.4 H z,l H), 1.83-1.46 (m, .7=3.8 
Hz, 6  H) 1.06 (d, J=  6.4 Hz, 6  H);
13C NMR (CDC13, 100 MHz): 5 157.1, 107.3, 101.9, 97.4, 89.3, 82.4, 65.6, 47.3, 28.3,
27.3,26.9, 23.8, 1.0.
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o o
TMS
CH3CN
KF
H
l-Cyclohexyl-4-isopropylidene-6-trimethylsiIyI-2,5-bexyne-l-one (42). 35 (1.00 g; 
3.57 mmol) and KF (230 mg; 3.96 mmol) was put in a 250 mL RB flask containing 
CH3CN (100 mL) and stirred at rt for 48 h. The reaction was then concentrated in 
followed by dilution with EtOAc (100 mL). The solution was then extracted with sat. 
NaHCCL (aq), H 2O, and brine. The organic layer was dried over N a2S0 4  for 0.5 h, 
gravity filtered, and then concentrated in vacuo leaving yellow oil. The oil was 
chromatographed with silica and hex:EtOAc (99:1) to afford 42 (680 mg; 3.17 mmol; 
91%). Anal. Calcd for: C i5H ,80 :  C, 84.07; H, 8.47; Found: C83.92; H, 8.81.
‘H NMR (CDCI3 , 400 MHz): 5 3.12 (s, 1 H), 2.42-2.34 (m, J =  3.9 Hz, 1 H), 2.10 (s, 3 
H), 2.05 (s, 3 H ) 1.96-1.93 (m, J =  2.6 Hz, 2 H), 1.76-1.72 (m, 7 =  3.9 Hz, 2 H), 1.63- 
1.60 (m, J =  3.9 Hz, 1 H) 1.44-1.151 (m, J =  2.6 Hz, 5 H);
l3C NMR (CDCI3 , 100 MHz): 8  192.2,164.3, 99.1, 89.5, 88.0, 81.5, 80.4, 78.7, 53.3, 
29.3, 26.8, 26.4, 24.3.
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l-CycIohexyI-7-cyclohexylidene-4-isopropylidene-9-trimethylsiIanyI-nona-2,5,8- 
triyn-l-one (43). A 100 mL 3 neck flask containing benzene (40 mL), trifluoro- 
methanesulfonic acid l-cyclohexylidene-3-trimethylsilanyl-prop-2-ynyl ester (5.416 g;
15.9 mmol), Hunig’s base (6.03 g; 5.7 mL; 46.6 mmol), Pd(PPh3)4 (349 mg; 0.30 mmol;
2.2 mol%), and Cul (15 mg; 0.0079 mmol) was degassed with Ar (g) for 45 min. To this 
solution was added, via syringe pump at 0.01 mL/min, l-Cyclohexyl-4-ethynyl-5-methyl- 
hex-4-en-2-yn-l-one (5.02 g; 17.13 mmol) dissolved in benzene (5 mL). When the 
addition was complete the reaction was diluted with Et20:H ex (1:1) (100 mL) and gravity 
filtered. The filtrate was extracted with 10% aqueous HC1 (3 x 100 mL) and combined 
aqueous layers were back extracted with Et20:hex (1:1) (2 x 30 mL) followed by 
extraction o f the organic layer with H20 , aqueous NaHCCfi, and brine. The organic layer 
was then dried over MgSCfi for 0.5 h and then concentrated in vacuo to afford dark 
brown oil. 43 was isolated after flash chromatography with silica and 5 L o f 0.6% 
EtOAc/hex as yellow oil (3.73 g; 9.31 mmol; 59%).
'H  NMR (CDC13, 400 MHz): 8  2.52-2.40 (m, 5 H), 2.10 (s, 3 H), 2.09 (s, 3 H), 2.00-1.18 
(m, 16 H), 0.18 (s, 9H );
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I3C NMR (CDCI3, 100 MHz): 8  192.4, 163.3, 161.8, 102.1, 101.4, 99 .1 ,97 .2 ,90 .3 ,90 .2 ,
87.8, 53.4, 33.9, 33.8, 29.4, 28.6, 27.2, 26.9, 26.5, 24.3, 1.0.
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l-CycIohexyl-7-cycIohexylidene-4-isopropylidene-nona-2,5,8-triyn-l-one (44). 43
(3.73 g; 9.37 mmol) and KF (600 mg; 10.3 mmol) were put in a 500 mL RB flask 
containing CH3CN (250 mL) and stirred at rt for 168 h. The reaction was then 
concentrated in vacuo followed by dilution with EtOAc (100 mL). The solution was 
extracted with sat. N aH C 0 3 (aq), H2O, and brine. The organic layer was dried over 
Na2S0 4  for 0.5 h, gravity filtered, and then concentrated in vacuo to afford yellow oil. 
The oil was chromatographed with silica and hex:EtOAc (99:1) to yield l-Cyclohexyl-7- 
cyclohexylidene-4-isopropylidene-nona-2,5,8-triyn-l-one as yellow oil (2.62 g; 7.88 
mmol; 84%).
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Pd(PPh3)4, Cul
1 -Cyclohexyl-7-cycIohexylidene-4,l O-isopropylidene-12-trimethylsilanyl-2,5,8,l 1 - 
dodecyn-l-one (45). A 100 mL 3 neck flask containing benzene (40 mL), trifluoro- 
methanesulfonic acid 2-methyl-1-trimethylsilanylethynyl-propenyl ester (4.12 g; 13.7 
mmol), H unig’s base (6.81 g; 6.5 mL; 53.9 mmol), Pd(PPh3) 4 (454 mg; 0.394 mmol; 2.2 
mol%), and Cul (18 mg; 0.095 mmol) was degassed with Ar (g) for 0.75 h. To this 
solution was added, via syringe pump at 0.01 mL/min, l-Cyclohexyl-7-cyclohexylidene- 
4-isopropylidene-nona-2,5,8-triyn-l-one (3.57 g; 15.1 mmol) dissolved in benzene (5 
mL). When the addition was complete the reaction was diluted with Et2 0 :Hex (1:1) (100 
mL) and gravity filtered. The filtrate was extracted with 10% aqueous HC1 (3 x 100 mL) 
and the combined aqueous layers were extracted with Et20:H ex (1:1) (2 x 30 mL) 
followed by extraction o f the organic layer with H 20 , aqueous N aH C 03, and brine. The 
organic layer was dried over M gS0 4 for 0.5 h and then concentrated in vacuo to afford 
dark brown oil. 45 was isolated after flash chromatography with silica and 5 L o f 0.6% 
EtOAc/hex as orange oil (2.38 g; 4.93 mmol; 36%). HRMS calcd for M +H+ of 
C33H42OSi 483.3083, found 483.3067.
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'H  NMR ( C D C I 3 , 400 MHz): 5 2.52-2.37 (m, 5H), 2.10 (s, 3H), 2.08 (s, 3H), 2.02 (s 
3H), 2.00 (s, 3H), 1.78-1.17 (m, 16H), 0.17 (s, 9H);
13C NMR (CDCI3 , 100 MHz): S 192.5, 161.7, 155.8, 102.7, 101.3, 99.0, 96.9, 90.4, 90.2,
89.1, 89.0, 87.5, 53.4, 34.0, 33.9, 30.8, 29.4, 28.7, 27.2, 26.9, 26.5, 24.3, 23.8, 23.7, 1.1.
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B. Compounds 56-69 
General synthesis for a-am ino phosphonates and a-am ino thiophosphonates: The
amine (1.0 eq) was weighed into a 100 mL RB flask with 20 mL o f toluene and 0.5 g of 
3 A molecular sieves then heated to dissolve the amine (if  necessary). When the amine 
was fully dissolved, the aldehyde (0.9 eq) was added via syringe while stirring and the 
solution would turn cloudy. After 20 min, the reaction was clear and checked by 'H  
NMR or LC MS for the formation of the imine. Once reaction was complete, the toluene 
was evaporated under reduced pressure and a thick oil was left behind. To the oil was 
added toluene (2-5 mL) and a stir bar, and the flask was then cooled to 0° C with an ice 
bath and purged with Ar(g). Either dimethyl phosphite (5-10 eq) or dimethyl 
thiophosphite (0.85 eq) was added via syringe and the reaction was stirred at ambient 
temperature for either 10 h for dimethyl thiophosphite or up to 4 d for dimethyl 
phosphite. All reactions were monitored by unlocked 3IP NM R and TLC (DBQ stain). 
When the reaction was complete, the solvent was removed under reduced pressure and 
excess phosphite was removed with a Kugelrohr to afford a thick oil. All reactions were 
purified with silica chromatography.
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0 ,0 -D im ethy l ester [2-M ethyI-l-(l-phenyl-ethylamino)-propyI]-phosphonothionate 
(56). [144]-a-M ethylbenzylamine (1.88 g, 15.5 mmol) was dissolved in 10 mL of 
toluene followed by the addition o f isobutyryl aldehyde (1.01 g, 1.27 mL, 13.96 mmol) 
and stirred at rt for 1 h. The reaction was concentrated to oil followed by the addition o f 
2 mL toluene, dimethyl thiophosphite (1.5 g, 11.87 mmol), and stirred at rt for 8 h. After 
concentrating to oil a silica column eluted with 5% EtOAc/hex afforded colorless oil 47 
as a mixture o f  diastereomers (10:7), (2.42 g, 8.02 mmol, 6 8 %). HRMS calcd for M+H+ 
ofC,4H24N02PS 302.1343, found 302.1246.
'H N M R  (CDCIs, 400 MHz): 5 7.39-7.21 (m, 5 H), 4.11-4.08 (m, 1H), 3.76 (d, J P0CH3 =
12.9 Hz, 1.5 H), 3.73 (d, J P0Cm  = 12.9 Hz, 1.5 H), 3.70 (d, JPOcm  = 12.9 Hz, 1.5 H), 3.68 
(d, JpocH3 = 12 .9  Hz, 1.5 H), 2.98 (dd, J PCH= 14.7, 2.6 Hz, 0.5 H), 2.71 (dd, J PCH = 11.0, 
2.6 Hz 0.5 H), 2.36-2.25 (m, J =  2.6 Hz, 0.5 H), 2.17-2.06 (m, J =  2.6 Hz, 0.5 H) 1.77 
(bs, 1H), 1.34 (d, J  = 6.4 Hz, 1.5 H), 1.30 (d, 6.4 Hz, 1.5 H), 1.10 (dd, J =  7.1, 2.0 Hz,
1.5 H), 0.98 (d, J =  7.1 Hz, 1.5 H), 0.93 (d, 7 = 7 .1  Hz, 1.5 H), 0.82 (d d ,7 = 6 .4 , 1.3 Hz,
1.5 H);
13C NMR (CDC13, 100 MHz): 5 146.8,145.8, 129.5, 129.2,128.7, 128.2, 128.1, 63.2 (d, 
J p c h  = 94.6 Hz), 63.0 (d, JPCH = 106.8 Hz), 57.2, 54.5 (d, J P0Cm  = 9.2 Hz), 54.1 (d,
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Jpocm — 9-2 Hz), 53.9 (d, Jpocm  -  6 . 1  Hz), 53.1 (d, Jpocm -  9.2 Hz), 30.1 (d, J =  9 
Hz), 30.0 (d, J =  9.1 Hz), 26.3, 24.1, 22.8 (d, J =  15.3 Hz), 22.4 (d, J =  15.3 Hz),
18.3,17.8.
31P NMR (CDC13, 171 MHz): 5 108.2, 104.9.
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0 ,0 -D im eth y l ester [2-M ethyI-l-(l-phenyl-ethylam ino)-propyl]-phosphonate (57).
[144]-a-M ethylbenzylamine (1.88 g, 15.5 mmol) was dissolved in 10 mL o f toluene 
followed by the addition o f isobutyryl aldehyde (1.01 g, 1.27 mL, 13.96 mmol) and 
stirred at rt for 1 h. The reaction was then concentrated and followed by the addition o f 2 
mL toluene, dimethyl phosphite (3.24 g, 29.46 mmol), and stirred at rt for 72 h. After 
concentrating to oil a silica column eluted with 1% MeOH/CHCL afforded colorless oil 
57 as a mixture o f  diastereomers (12:9), (2.23 g, 7.42 mmol, 48%). HRMS calcd for 
M+H+ o f C 14H 2 4 N O 3P  286.1572, found 286.1549.
'H  NMR ( C D C I 3 , 400 MHz): 8  7.26-7.21 (m 5 H), 4.10-4.07 (m, 1H), 3.71 (d, JP0CH3 =
10.4 Hz, 3 H), 3.70 (d, Jpocm = 10.4 Hz, 3 H), 2.60 (m, 1 H), 2.12-2.05 (m, 1 H), 1.36 (d, 
7  = 6.4 Hz, 3 H ), 1.09 (d, 6.4 Hz, 3 H), 1.01 (d, 7 = 6 .4  Hz, 3 H);
13C N M R (C D C 13, 100 MHz): 5 146.4,145.5, 129.8, 129.2,128.9, 128.3, 128.1, 53.8 (d, 
Jpocm  = 9.2 Hz), 53.1 (d, Jpocm  = 6 . 1  Hz), 53.0 (d, Jpocm  = 6 . 1  Hz), 52.7 (d, Jpocm  =
6.1 Hz), 51.5 (d, Jpch= 138.8 Hz), 51.1 (d, JPCH = 120.8 Hz), 29.9 (d, 7 =  9.1 Hz), 29.6 
(d, 7 =  9.1 Hz), 26.2, 24.2, 22.4 (d, 7 =  12.2 Hz), 21.9 (d, 7 =  12.2 Hz).
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31P NM R (CDCI3 , 171 MHz): 5 33.0, 31.3.
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0 ,0 -D im eth y l ester [l-(2-Hydroxy-l-phenyI-ethylamino)-2-methyI-propyI]- 
phosphonothionate (58). [144]-Phenylglycinol (1.13 g, 18.3 mmol) dissolved in 10 mL 
o f toluene followed by the addition o f isobutyryl aldehyde (0.59 g, 8.20 mmol) and 
stirred at rt for 1 h. The reaction was then concentrated, followed by the addition o f 2 mL 
o f toluene, dimethyl thiophosphite (0.93 g, 7.38 mmol), and stirred at rt for 8  h. The 
reaction was then concentrated to oil followed by a silica column eluted with 1 % 
M eOH/CHCb to afford colorless oil 58 as a mixture o f diastereomers (11:8), (2.23 g,
7.42 mmol, 48%). HRMS calcd for M+H+ o f C 14H24N03PS 318.1292, found 318.1201.
'H  NMR (CDC13, 400 MHz): 8  7.33-7.23 (m 5 H), 4.14-3.98 (m, 1H), 3.72 (d, Jpocm  =
12.9 Hz, 1.5 H), 3.71 (d, JPOcm = 12.9 Hz, 1.5 H), 3.69-3.66 (m, 7  = 3.9 Hz, 2 H) 3.62-
3.55 (m ,7 =  3.9 Hz, 1 H) 3.59 (d , J POCm  = 12.9 Hz, 1.5 H), 3.55 (d , J P0Cm  = 12.9 Hz,
1 .5 H), 2.95 (dd, JPCH = 16.2, 2.6 Hz, 0.5 H), 2.81 (dd, JPCH = 9.7, 2.6 Hz, 0.5 H), 2.33- 
2.14 (m, 7  = 7.2 Hz, 1 H), 1.09 (d, 7 =  6.4 Hz, 1.5 H), 1.01 (d, 6.4 Hz, 1.5 H), 0.92 (d ,7  =
6.4 Hz, 1.5 H), 0.85 (d, 7 =  6.4 Hz, 1.5 H);
I3CN M R (C D C 13, 100 MHz): 5 141.6, 141.4, 129.4, 129.3, 129.1, 129.0, 128.7, 6 8 .8 ,
6 8 .2 , 64.9, 64.5, 55.9 (d, JPCH = 134.3 Hz), 57.7 (d, J PCH = 152.6 Hz), 54.0 (d, JP0Cm  =
6.1 Hz), 53.9 (d, J P o c h 3 = 9.2 Hz), 53.2 (d, J P o c h 3 = 6.1 Hz), 53.1 (d, J P o c h 3 = 9.2 Hz),
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30.4 (d, J =  6.1 Hz), 29.5 (d, J  = 6.1 Hz), 21.8 (d, J =  12.2 Hz), 21.2 (d, J  = 12.2 Hz),
19.6, 18.5.
31P NMR (CDC13, 171 MHz): 5 106.3, 103.6.
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O,O-Dimethyl ester [3-M ethyl-l-(l-phenyl-ethylam ino)-butyl]-phosphonothionate 
(59). [144]-a-M ethylbenzylamine (1.13 g, 9.3 mmol) dissolved in 10 mL o f toluene 
followed by the addition o f 3-methyl-butyraldehyde (0.81 g, 9.3 mmol) and stirred at rt 
for 1 h. The reaction was then concentrated, followed by the addition o f 2 mL o f toluene, 
dimethyl thiophosphite (1.06 g, 8.37 mmol), and stirred at rt for 10 h. After 
concentrating to oil a silica column eulated with 0.5% EtOAc/hex afforded colorless oil 
59 with partial separation o f diastereomers (10:8), (2.19 g, 6.94 mmol, 75%). HRMS 
calcd for M+H+ o f C i5H 26N 0 2PS 316.1500, found 316.1555.
Major isomer:
‘H NMR (CDC13, 400 MHz): 5 7.35-7.18 (m 5 H), 4.07 (dq, 7 =  6.4, 1.9 Hz, 1H), 3.74 
(d, Jpocm = 12.9 Hz, 3 H), 3.68 (d, JP0Cm  = 12.9 Hz, 3 H), 3.02 (dt, J PCH = 8.4, 5.2 Hz, 1 
H), 1.92-1.86 (m, 7  = 6.4 Hz, 1 H), 1.66-1.54 (m, 7  = 5.2 Hz, 1 H), 1.42 (d, 7 = 8 .4  Hz, 2 
H), 1.31 (d, 6.4 Hz, 3 H), 0.89 (d, 7  = 6.4 Hz, 3 H), 0.84 (d, 7 =  6.4 Hz, 3 H);
13C N M R (C D C13, 100 MHz): 5 145.9, 129.3, 128.5, 128.2, 57.0, 56.3 (d ,7 PC//=  103.8 
Hz), 54.8 (d, 7PocH3 = 6 .1 Hz), 53.7 (d, JPoch3 ~  9.2 Hz), 41.3 (d, 7 =  9.2 Hz), 26.0, 24.8,
24.6,22.0.
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3IP NMR (CDCI3 , 171 MHz): 5 109.4.
Minor isomer:
‘H NMR (CDCI3, 400 MHz): 5 7.35-7.21 (m 5 H), 4.07 (dq, J = 6.4, 1.9 Hz, 1H), 3.75 
(d, J Pocm  = 12.9 Hz, 3 H), 3.02 (dt, JPCH = 8.4, 5.2 Hz, 1 H), 1.92-1.86 (m, J =  6.4 Hz, 1 
H), 1.64-1.56 (m, J =  5.2 Hz, 1 H), 1.41 (d, J =  8.4 Hz, 2 H), 1.31 (d, 6.4 Hz, 3 H), 0.88 
(d, J =  6.4 Hz, 3 H), 0.83 (d, J =  6.4 Hz, 3 H);
l3C NMR (CDCI3, 400 MHz): 5 146.6, 129.4, 128.1, 128.0, 56.9, 56.5 (d, J PCH = 116.0 
Hz), 54.8 (d, J Pocm  = 9.2 Hz), 53.8 (d, JP0Cm  = 6.1 Hz), 41.3 (d, J =  9.1 Hz), 25.9, 24.8,
24.2,23.1.
31PN M R (C D C 13, 400 MHz): 6  106.1.
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0,0 -D im eth y l ester [3-M ethyl-l-(l-phenyl-ethylam ino)-butyI]-phosphonate (60).
[144]-a-M ethylbenzylamine (1.88 g, 15.5 mmol) dissolved in 10 mL o f toluene followed 
by the addition o f  3-methyl-butyraldehyde (1.30 g, 15.45 mmol) and stirred at rt for 1 h. 
The reaction was then concentrated followed by the addition o f 2 mL o f toluene, 
dimethyl phosphite (3.41 g, 31.02 mmol) and stirred at rt for 96 h. After concentrating to 
oil a silica column eluted with 70% CHC^/hex afforded colorless oil 60 as a mixture o f 
diastereomers (10:4), (2.93 g, 9.81 mmol, 63%). HRMS calcd for M +H+ o f C ^ N C ^ P  
300.1728, found 300.1697.
'H  NMR (CDCI3, 400 MHz): 5 7.27-7.14 (m 5 H), 4.10 (dq, J =  6.4, 3.2 Hz, 1 H), 3.71 
(d, Jpocm  = 10.4 Hz, 3 H), 3.70 (d, JPOCm  = 10.4 Hz, 3 H), 2.65-2.59 (m, J PCh =%A, 3.2 
Hz, 1 H), 1.77-1.67 (m, 7 = 6 .4  Hz, 1H ), 1.62-1.52 (m, J =  6.4 Hz, 2 H), 1.31 (d, 6.4 Hz, 
3 H), 0.76 (d , J  = 7.1 Hz, 3 H), 0.35 (d, J  = 7.1 Hz, 3 H);
13C N M R (C D C13, 100 MHz): 5 146.2, 145.8, 129.4, 129.3, 128.3, 128.2, 128.1, 128.0,
57.2, 56.7 (d, Jpocm ~  9.2 Hz), 54.1 (d, Jpocm  = 6 . 1  Hz), 53.7 (d, Jpocm  = 6 . 1  Hz), 53.5 
(d, Jpocm  = 6.1 Hz), 50.8 (d, JPCH = 152.6 Hz), 50.6 (d , J PCH = 146.5 Hz), 41.2, 40.8, 
25.9, 25.6, 25.2, 24.8, 24.6, 23.9, 21.8.
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31P NMR (CDCI3, 171 MHz): 8  33.1, 32.0.
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0 ,0 -D im eth y l ester [l-(2-Hydroxy-l-phenyl-ethylam ino)-3-m ethyl-butyI]- 
phosphonothionate (61). [144]-Phenylglycinol (1.20 g, 8.73 mmol) dissolved in 10 mL 
o f toluene followed by the addition o f 3-methyl-butyraldehyde (0.745 g, 8.69 mmol) and 
stirred at rt for 1 h. The reaction was then concentrated followed by the addition o f 2 mL 
o f toluene, dimethyl thiophosphite (0.99 g, 7.87 mmol) and stirred at rt for 8  h. After 
concentrating to oil a silica column eluted with C H C I 3 afforded colorless oil 61 as a 
mixture o f  diastereomers (2.08 g, 6.61 mmol, 76%). HRMS calcd for M +H+ of 
Q 5H26N O 3PS 331.1371, found 331.1333.
'H  NMR ( C D C I 3 , 400 MHz): 6  7.33-7.23 (m 5 H), 4.16-4.12 (m, 1H), 4.02 (dd, J = 7.1,
2.6 Hz 2 H), 3.76 (d, JPOcm  = 12.9 Hz, 1.5 H), 3.73 (d, J P O c h 3 = 12.9 Hz, 1.5 H), 3.66 (d, 
Jpocm  = 12.9 Hz, 1.5 H), 3.64 (d , J P O C h s  = 12.9 Hz, 1.5 H), 3.04-2.97 (m, J P C H =  8.4, 2 . 6  
Hz, 1 H), 1.88-1.74 (m, .7=7.1 Hz, 1 H), 1.62-1.34 (m, J =  7.1 Hz, 2 H), 0.86 (d, 7 =  7.1 
Hz, 1.5 H), 0.83 (d, 7.1 Hz, 1.5 H), 0.81 (d, J = 6 A  Hz, 1.5 H), 0.48 (d, .7= 6 .4  Hz, 1.5 
H);
13CN M R (C D C 13, 100 MHz): 5 141.5, 141.3, 129.6, 129.0, 128.9, 128.8, 128.7,68.5,
67.8, 64.2, 63.4 (d, Jpocm ~ 9.2 Hz), 56.9 (d, J p c h  ~  119.0 Hz), 56.7 (d, J P c h  = 1 12.9
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Hz), 54.7 (d, Jpocm  = 9.2 Hz), 54.4 (d, J P0Cm  = 6.1 Hz), 53.9 (d, J P0Cm  = 9.2 Hz), 41.2 
(d, J =  6 .1 Hz), 41.0 (d, /  = 6 .1 Hz), 26.2, 26.0, 24.9, 24.8, 24.1, 23.1.
3IP NMR (CDCI3 , 171 MHz): 5 107.3, 105.3.
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0 ,0 -D im eth y l ester [l-(2-Hydroxy-l-phenyl-ethylam ino)-3-m ethyl-butyl]- 
phosphonate (62). [144]-Phenylglycinol (1.74 g, 12.7 mmol) dissolved in 10 mL o f 
toluene was put into a 50 mL RB, followed by the addition o f 3-methyl-butyraldehyde 
(0.98 g, 11.43 mmol) and stirred at rt for 1 h. The reaction was then concentrated 
followed by the addition of 4 mL o f toluene, dimethyl phosphite (2.52 g, 22.86 mmol), 
and stirred at rt for 72 h. After concentrating to oil a silica column eluted with 1% 
MeOH/CHCL afforded colorless oil 62 as a mixture o f diastereomers (4:1), (1.65 g, 5.24 
mmol, 46%). HRMS calcd for M+H+ of C i5H 26N 0 4P 315.1599, found 315.1632.
‘H NMR (CDC13, 400 MHz): § 7.34-7.23 (m 5 H), 4.11-4.00 (m, 1H), 4.02 (dd, 7  = 7.1,
2.6 Hz 2 H), 3.81 (d, JP0Cm  = 10.4 Hz, 1.5 H), 3.75 (d, JP0Cm  = 10.4 Hz, 1.5 H), 3.71 (d, 
Jpocm  = 10.4 Hz, 1.5 H), 3.70 (m, 2 H), 3.66 (d, JPOcm  = 10.4 Hz, 1.5 H), 2.93-2.84 (m, 
J pch= 8 A B z , 1 H), 1.83-1.71 (m, 7 = 6 .4  Hz, 1 H), 1.64-1.45 (m, 7 =  6.4 Hz, 2 H), 0.86 
(d, 7 =  6.4 Hz, 1.5 H), 0.84 (d, 6.4 Hz, 1.5 H), 0.78 (d ,7 = 6 .4  Hz, 1.5 H), 0.55 (d ,7 = 6 .4  
Hz, 1.5 H);
13C NMR (CDCI3 , 100 MHz): 5 141.8, 141.5, 129.6, 129.4, 129.3, 128.8, 128.7, 68.5,
67.8, 65.2, 63.5, 63.4, 54.5 (d, Jpocm ~ 6 . 1  Hz), 54.2 (d, Jpocm  = 6 . 1  Hz), 53.6 (d, Jpocm
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= 6.1 Hz), 53.5 (d, Jpocm  = 9.2 Hz), 51.9, (d, J PCh=  149.5 Hz), 50.9 (d, J PCH = 152.6 
Hz), 41.4, 40.8, 26.0, 24.7, 23.8, 23.4, 21.9.
31P NMR (CDCI3, 171 MHz): 5 32.7, 32.0.
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0 ,0 -D im eth y l ester [l-(2-Hydroxy-l-phenyl-propylamino)-3-phenyI-methyl]- 
phosphonate (63). L-threonine methyl ester (1.039 g, 7.8 mmol) dissolved in 10 mL o f 
CH2CI2 was put into a 50 mL RB, followed by the addition o f benzaldehyde (0.79 mL, 
0.828 g, 7.8 mmol), K2CO3 (1.62 g, 11.7 mmol), and stirred at rt for 3 h. The reaction 
was then concentrated followed by the addition o f 2  ml o f toluene, dimethyl 
thiophosphite (0.84 g, 6 . 6 6  mmol), and stirred at rt for 10 h. After concentrating to oil a 
silica column eluted with 70% CH^Chihex afforded colorless oil 63 as a mixture of 
diastereomers (8:3), (1.65 g, 5.24 mmol, 46%). HRMS calcd for M+H+ o f C i4H 23N0 5PS 
348.1034, found 348.1046.
Major isomer:
'H  NMR (CDCI3, 400 MHz): 5 7.40-7.20 (m, 5H), 4.07 (d, 1 H, JPCH = 14.8 Hz), 3.86- 
3.79 (m, 1H), 3.75 (d, 3 H, J p o c h s  = 13.6 Hz), 3.37 (s, 3 H), 3.33 (d, 3 H, J P0Cm  =12.8 
Hz), 2.95 (d, 1 H, J —  6.4 Hz), 1.15 (d, 3 H, 7 =  6.4 Hz);
13CN M R (C D C 13, 100 MHz): 5 173.20, 134.9, 133.8, 129.2, 128.7, 128.6, 128.4,68.2,
66.7, 65.9 (d, J CP = 127.50 Hz), 54.2 (d , J P 0C H 3 = 9.1 Hz), 53.7 (d , J p o c h s  = 6.1 Hz) 51.8,
19.1.
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3!P NMR (CDCI3 , 171 MHz): 5 97.2.
Minor isomer:
'H  NM R (CDCI3, 400 MHz): 5 7.40-7.20 (m, 5H), 4.11 (d, J PCH = 14 Hz, 1 H), 3.75-3.70 
(m, 1 H), 3.67 (s, 3 H), 3.64 (d, J PCH3 = 13.6 Hz, 3 H), 3.52 (d, J POCm = 13.6 Hz, 3 H), 
2.99 (d, 1 H, 7  = 6 .4  Hz) 1.13 (d, J - 6.4 Hz, 3 H);
13CN M R (C D C 13, 100 MHz): 6  173.0, 134.9, 133.8, 129.2, 129.1, 128.7, 128.4,67.9,
66.6,64.5 (d, J CP = 118.4 Hz), 54.3 (d, JPOcw  = 6.1 Hz), 53.6 (d, JP0Cm  = 6 . 1  Hz) 51.9,
19.3.
31P NMR ( C D C I 3 , 171 MHz): 6  96.8.
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0 ,0 -D im eth y l ester [l-(l-PhenyI-ethylamino)-butyI]-phosphonothionate (64). [144]-
a-M ethylbenzylamine (1.88 g, 15.51 mmol) dissolved in 10 mL o f toluene was put into a 
50 mL RB, followed by the addition o f rc-butyraldehyde (1.062 g, 14.73 mmol) and 
stirred at rt for 1 h. The reaction was then concentrated followed by the addition of 
dimethyl thiophosphite (1.67 g, 13.26 mmol), and stirred at rt for 8  h. After 
concentrating to oil a silica column eluted with 1% EtOAc/hex afforded colorless oil 64 
as partial seperation o f diastereomers (9:19), (3.38 g, 11.21 mmol, 85%). H R M S  calcd 
for M+H+ o f C 14H 2 4N O 2 P S  302.1343, found 302.1301.
Major isomer:
'H  NM R (CDCI3, 400 MHz): 5 7.35-7.21 (m, 5 H), 4.03 (q, J =  6.4, 1 H), 3.74 (d, J P0CH3 
= 12.9 Hz, 3 H), 3.67 (d, JPOcm = 12.9 Hz, 3 H), 2.92 (dt, JPCh = 8.4, 2.6 Hz, 1 H), 1.84- 
1.37 (m, J =  7.1 Hz, 5 H), 1.32 (d , J =  6.4 Hz, 3 H), 0.90 ( t , J =  7.1 Hz, 3 H);
13CN M R (C D C 13, 1 0 0  MHz): 8  146.2, 129.5, 128.2, 128.0, 58.0 (d, J PCh = 116.0 Hz),
56.6, 54.8 (d, JPOcm  = 6.1 Hz), 54.1 (d, JP0Cm  = 6.1 Hz), 33.4 (d, 7 =  6.1 Hz), 25.0, 20.5,
15.2.
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31P NM R (CDCI3, 171 MHz): 5 105.0.
M inor isomer:
'H NMR (CDCI3, 400 MHz): 8  7.30-7.20 (m, 5 H), 4.10 (q, 7  = 6.4, 1 H), 3.77 (d, JP0Cm  
= 12.9 Hz, 3 H), 3.72 (d, JP0Cm = 12.9 Hz, 3 H), 2.77 (dt, JPCH = 8.4, 3.2 Hz, 1 H), 1.63 
(bs, 1 H), 1.58-1.49 (m, 7 = 7 .1  Hz, 4 H), 1.31 (d, 7 =  6.4 Hz, 3 H), 0.71 (t, 7 = 7 .1  Hz, 3 
H);
13C N M R (C D C 13, 100 MHz): 5 146.0, 129.3, 128.4, 128.1, 57.8 (d, J PCH = 131.2 Hz),
57.4, 54.7 (d, JPOcm  = 9.2 Hz), 53.8 (d, J P0Cm  = 9.2 Hz), 34.3 (d, 7 =  6 . 1  Hz), 26.1, 2 0 .1 ,
14.8.
3 IPN M R (C D C 13, 171 MHz): 5 108.6.
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0 ,0 -D im eth y l ester [l-(l-Phenyl-ethylam ino)-butyl]-phosphonate (65). [144]-a- 
Methylbenzylamine (1.88 g, 15.51 mmol) dissolved in 10 mL o f toluene was put into a 
50 mL RB, followed by the addition o f n-butyraldehyde (1.062 g, 14.73 mmol) and 
stirred at rt for 1 h. The reaction was then concentrated followed by  the addition o f 2 mL 
o f toluene, dimethyl phosphite (3.24 g, 29.45 mmol), and stirred for 96 h. After a 
concentrating to oil a silica column eluted with 1% M eOH/CHCI3 afforded colorless oil 
65 as a mixture o f diastereomers (9:10), (3.30 g, 11.56 mmol, 75%). HRMS calcd for 
M+H+ o f C i4H24N 0 3P 286.1572, found 286.1602.
‘H NMR (CDCI3, 400 MHz): 5 7.28-7.15 (m 5 H), 4.08 (dq, 7  = 6.4, 2.6 Hz, 1 H), 3.71 
(d, Jpoch3 = 10.4 Hz, 3 H), 3.70 (d, Jpocm = 10.4 Hz, 3 H), 2.62 (dt, J p c h  ~  9.1, 3.8 Hz, 1 
H), 1.58-1.32 (m, 7  = 7.1 Hz, 4 H), 1.26 (d, 7 =  6.4 Hz, 3 H), 0.67 (t, 7 = 7 .1  Hz, 3 H);
!3C NMR (CDCI3, 100 MHz): 8  145.9, 129.4, 128.2, 128.1, 57.4, 53.7 (d, J P0CH3 = 9.2 
Hz), 53.6 (d, Jpocm  = 6.1 Hz), 52.3 (d, J PCH = 143.4), 34.0 (d, 7 =  6 . 1  Hz), 25.7, 2 0 .1 , 
14.7.
3IP NMR ( C D C I 3 , 171 MHz): 5 37.2, 31.6.
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0 ,0 -D im eth y l ester [l-(2-Hydroxy-l-phenyl-ethylam ino)-butyl]-phosphonothionate 
(6 6 ). [144]-Phenylglycinol (3.52 g, 25.69 mmol) dissolved in 10 mL o f toluene was put 
into a 50 mL RB, followed by the addition o f ft-butyraldehyde (1.80 g, 24.9 mmol) and 
stirred at rt for 1 h. The reaction was then concentrated followed by the addition o f 2 mL 
toluene, dimethyl thiophosphite (2.92 g, 23.12 mmol), and stirred at rt for 7 h. After 
concentrating to oil a silica column eluted with 5% EtOAc/hex afforded colorless oil 66 
as a mixture o f  diastereomers (10:6), (3.38 g, 24.9 mmol, 85%). HRMS calcd for M+H+ 
o f C 14H24NO 3PS 318.1292, found 318.1331.
*H NMR ( C D C I 3 , 400 MHz): S 7.34-7.26 (m 5 H), 4.03-4.00 (m, 7  = 7.1 Hz, 1 H), 3.78- 
3.70 (m, J =  7.1 Hz, 2 H), 3.68 (d, JPOcm = 12.9 Hz, 1.5 H), 3.66 (d, JP0Cm  = 12.9 Hz, 3 
H), 3.60 (d, JpocH3 ~  12.9 Hz, 1.5 H), 3.58 (d, J Poch3 = 12.9 Hz, 1.5 H), 2.95 (m, J Pch ~ 
7.7U z, 1 H), 1.84-1.71 (m, 7 = 7 .1  Hz, 2 H), 1.65-1.37 (m, 7  = 7.1 Hz, 2 H), 0.87 ( t , J  =
7.1 Hz, 3 H), 0.74 (t, 7 =  7.1 Hz, 3 H);
l3C NMR (CDCI3, 100 MHz): 6  141.4, 141.3, 129.6, 129.5, 128.9, 128.8, 128.7, 6 8 .6 ,
67.9, 64.4, 63.3, 58.4 (d, JPch = 109.9 Hz), 58.2 (d, JPch = 119.0 Hz), 54.8 (d, JPocm  =
9.2 Hz), 54.6 (d, J Pocm ~ 6.1 Hz), 54.3 (d, JPoch3 = 6.1 Hz), 53.9 (d, J Pocm  = 9.2 Hz),
34.2 (d, 7 =  6.1 Hz), 33.2 (d ,7 = 6 .1  Hz), 20.6, 20 .5 ,20 .2 ,20 .1 , 15.2, 14.8.
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31P  N M R  ( C D C I 3 , 17 1  M H z ) :  8  1 0 6 . 5 ,  1 0 4 .3 .
1 5 5
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MeO
M e O ^ J / S  .OH 
P r
3 R S ,  1 R -  0 ,0 -D im eth y l ester [(2-Hydroxy-l-phenyl-ethylamino)-phenyl-methyl]- 
phosphonothionate (67). [144]-Phenylglycinol (0.51 g, 3.72 mmol) dissolved in 10 mL 
of toluene was put into a 50 mL RB, followed by the addition o f  benzaldehyde (0.40 g, 
3.74 mmol) and stirred at rt for 1 h. The reaction was then concentrated followed by the 
addition o f 3 mL o f toluene, dimethyl thiophosphite (0.46 g, 3.79 mmol), and stirred at rt 
for 7 h. After concentration to oil a silica column eluted with 50% hex/Et2 0  afforded 
colorless oil 67 as a mixture o f diastereomers (0.99 g, 2.77mmol, 56%). Anal. Calcd for 
C 17H22NO 3PS: C, 58.11; H, 6.31; N, 3.99. Found: C, 57.90; H, 6.42; N, 3.89.
Major isomer:
'H  NM R (CDCI3, 400 MHz): 5 7.33-7.21 (m, 10 H), 4.20 (d, JPCH = 17.2 Hz, 1H), 4.01- 
3.95 (m, 1 H), 3.78 (d, JP0CH3 = 15.6 Hz, 3 H), 3.79-3.73 (m, 1H), 3.32 (d, J P O c h 3 =12.8 
Hz, 3 H), 2.64 (br s, 1 H);
13CN M R (C D C 13, 1 0 0  MHz): 6  140.0, 135.7, 128.5, 128.4, 128.3, 128.1, 127.7, 127.4,
66.0, 62.9 (d, JPC = 116.0 Hz), 62.5, 62.4, 54.5 (d, JP0CH3 = 6 .1 Hz), 53.8 (d, J POCH3 = 9.1 
Hz);
31 P NM R (CDCL, 171 MHz): 6  100.5.
156
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Minor isomer:
!H NMR (C D C I3 , 400 MHz): 5 7.36-7.21 (m , 10H), 3.97 (d , JPCH = 18.8 Hz, 1 H), 3.74 
(d , Jpocm  = 12.8 Hz, 3 H) 3.68-3.58 (m, 3H), 3.45 (d , JPOcm  = 12.8 Hz, 3 H), 2.28 (b r  s, 
1H);
13CN M R (C D C 13, 100 MHz): 5 138.7, 134.4, 129.0, 128.9, 128.7, 128.4, 128.3, 127.9,
127.6, 67.0, 62.3 (d , J p c ~  1 2 2 . 0  Hz), 61.5, 61.3, 54.1 (d , Jpocm  = 6 . 1  Hz) 53.3 (d , Jpocm  
= 6.1 Hz);
31P NMR (CDCI3, 171 MHz): 5 98.1.
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MeO 
MeO^ I / S  
P
0 ,0 -D im eth y l ester [[144]-Phenyl-(l-phenyl-ethylamino)-methyl]- 
phosphonothionate (68). [ 144]-Phenylglycinol (0.75 g, 6.2 mmol) dissolved in 10 mL 
o f toluene was put into a 50 mL RB, followed by the addition o f benzaldehyde (0.66 g,
6.2 mmol), and stirred at rt for 1 h. The reaction was then concentrated followed by the 
addition o f 2 mL o f toluene, dimethyl thiophosphite (0.78 g, 6.2 mmol), and stirred at rt 
for 8  h. After concentrating to oil a silica column eluted with 2% Et2 0 /hex to yield 
colorless oil 68 as a mixture o f diastereomers (8:2), (1.32 g, 3.95 mmol, 64%). HRMS 
calcd for M +H+ o f C 17H 22NO 2PS calcd for 336.1187, found 336.1194.
'hi NMR (CDCI3, 400 MHz): 5 7.37-7.21 (m, 10 H), 4.24 (d, Jpch =19 .2  Hz, 1 H), 3.93 
(q, J =  6.4 Hz, 1 H), 3.84 (d, JP0Cm  = 12.8 Hz, 3 H), 3.36 (d, JP0Cm  = 12.8 Hz, 3 H), 2.45 
(br s, 1H), 1.36 (d, / =  6.4 Hz, 3 H);
13C N M R (C D C 13, 100 MHz): 5 145.0, 135.9, 128.4, 128.4, 128.3, 128.1, 127.0, 126.7,
62.6 (d, J Cp = 115.3 Hz), 55.2 (d, JP0Cm  = 9.1 Hz), 54.1 (d, JPOcm  = 6.1 Hz), 53.7, 23.0;
3 IPN M R (C D C 13, 171 MHz): 5101.6.
158
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
0 ,0 -D im eth y l ester 2-{[(Dimethoxy-thiophosphoryl)-phenyl-methyl]amino}-3- 
hydroxy-propionate (69). To a suspension o f L-serine methyl ester hydrochloride (0.54 
g, 3.47 mmol) in THF (15 mL) was added TEA (0.48 mL, 0.35 g, 3.44 mmol). The 
reaction was stirred at 0 °C for 30 min and filtered rapidly under vacuum. The solvent 
was evaporated to dryness to give L-serine methyl ester as an off-yellow oil (0.34 g, 2.82 
mmol). To a solution o f  L-serine, methyl ester in CH2CI2 (5 mL) was added 
benzaldehyde (0.27 mL, 0.28 g, 2.66 mmol) and molecular sieves (3 A, 0.5 g). The 
reaction mixture was stirred at rt for 2 h and filtered through Celite. Dimethyl 
thiophosphite 5 (0.24 mL, 0.36 g, 2.85 mmol) was added and the reaction mixture was 
stirred at 0 °C for 12 h. The solvent was evaporated to dryness to give crude product 
(0.688 g) as yellowish oil that was purified by column chromatography (30% hex/Et2 0 ) 
to yield 69 as partially separated diastereomers. Anal. Calcd for iCnL^oNOsPS: C, 46.84; 
H, 6.05; N, 4.20; Found: C, 46.49; H, 5.96; N, 4.21.
Major isomer:
'H  NMR (CDCI3, 400 MHz): 5 7.39-7.26 (m, 5H), 4.16 (d, J C p h  = 20.4 Hz, 1 H), 3.81-
3.55 (m, 2H), 3.75 (d, JP0Cm  = 13.2 Hz, 3 H), 3.60 (s, 3H), 3.45-3.32 (m, 1H), 3.38 (d, 
Jpocm  = 13.6 Hz, 3 H), 2.91 (br s, 1H);
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13C N M R (C D C 13, 100 MHz): 5 172.4, 134.7, 128.5, 128.5, 128.3, 63.7 (d, J PC = 128.1 
Hz), 61.6, 60.2, 54.3 (d, JPOCm  = 9.1 Hz), 53.7 (d, J POCH3 = 6.1 Hz), 52.2;
31P NMR (CDCI3, 171 MHz): 8  97.8.
Minor isomer:
'H  NMR (CDCI3, 400 MHz)
3.64 (m, 2 H), 3.69 (d , J P0Cm  
H), 3.35-3.30 (m, 1H);
13C N M R (C D C 13, 100 MHz): 5 172.6, 134.2, 129.1, 129.1, 128.4, 128.3, 64.2 (d, JPC = 
119.1 Hz), 63.1,60.0, 54.3 (d, JPOCH3 = 6.1 Hz), 53.7 (d, JP0CH3 = 6.1 Hz), 52.1;
31P NMR (CDC13, 171 MHz): 8  97.2.
: 8 7.42-7.26 (m, 5H), 4.29 (d, JPch = 15.6 Hz, 1 H), 3.74- 
=13.2 Hz, 3 H), 3.70 (s, 3H), 3.53 (d, J POcm  = 13.2 Hz, 3
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D. Compounds 70-72
General synthesis for a-am ino phosphonic and a-am inothiophosphonic acids:
a-A m inophosphonate or a-aminothiophosphonate (0.7-1.7 mmol) was placed into a 50 
mL RJB flask with 10 mL o f acetone and a water condenser. To this solution was added 
potassium ethyl xanthate (0.9 eq) and then the reaction was refluxed for 8-20 h while 
monitoring by reaction with unlocked 3!P NMR until the reaction was complete. The 
work up for each reaction was specific for the compound and is listed with the spectral 
data.
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[2-M ethyl-l-(l-phenyl-ethyIamino)-propyl]-phosphonothioic acid O-methyl ester 
(70). Compound 56 (0.44 g, 1.48 mmol) was reacted with PEX (0.23 mg, 1.4 mmol) at 
reflux for 8 h and then concentrated under reduced pressure to afford light yellow oil.
The oil was dissolved in Et2 0  and a white powder crashed out o f  solution. The
1 13 31precipitate was isolated and then analyzed by H, C, and P NM R showing a mixture of 
4 diasteromers (10:8:7:5), (0.086 g, 0.30 mmol, 21%). HRMS calcd for M +H+ o f 
C 13H 22NO 2PS 288.1187, found 288.1225.
‘H NMR (CDCI3, 400 MHz): 5 7.70-7.35 (m, 5H), 4.68 (q, J =  6.4 Hz, 0.5 H), 4.38 (q, 7  
= 6.4 Hz, 0.5 H), 3.72 (d, 7  = 12.9 Hz, 0.75 H), 3.70 (d, 7  = 12.9 Hz, 0.75 H), 3.47 (d, 7  = 
12.9 Hz, 0.75 H), 3.34 (d, 7  = 12.9 Hz, 0.75 H), 2.85-2.74 (m, 1 H), 2.53-2.38 (m, J=  7.1 
Hz, 1 H), 1.97-1.90 (m, .7=7.1 Hz, 3 H), 1.88 (d, 7 =  7.1 Hz, 0.75 H), 1.29 (d, 7 = 7 .1  Hz, 
0.75 H), 1.27 (d, 7 = 7 .1  Hz, 0.75 H), 1.17 (d, 7 = 7 .1  Hz, 0.75 H), 1.09 (d ,7 = 7 .1  Hz, 
0.75 H), 1.06 (d, 7 =  7.1 Hz, 0.75 H), 0.81 (d, 7 =  7.1 Hz, 0.75 H), 0.76 (d ,7 = 7 .1  Hz, 
0.75 H).
I3C N M R (C D C 13, 100 MHz): 5 137.6, 137.3, 137.0, 136.6, 130.7, 130.6, 130.5, 130.3, 
130.2, 129.9, 129.8, 129.0, 128.9, 6 6 .2 , 65.3, 65.1, 64.3, 62.5 (d, JPCH= 103.8 Hz), 62.4
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(d, J p c h  ~  119.0 Hz), 61.5 (d, J p c h  ~ 109.9 Hz), 61.1 (d, J p c h  ~  128.2 Hz), 53.3 (d, J p o c h s  
= 6.1 Hz), 53.1 (d, J p o c h 3 — 6.1 Hz), 52.8 (d, Jpocm  -  6.1 Hz), 51.9 (d, Jpocm — 6.1 Hz), 
30.0, 29.4, 28.1, 23.7, 23.5, 23.0, 22.2, 21.5, 21.4, 21.1, 21.0, 18.7, 18.5.
31P NMR (CDC13, 171 MHz): 5 74.6, 72.3, 71.6, 68.2
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[l-(l-PhenyI-ethyIamino)-butyl]-phosphonic acid monomethyl ester (71). Compound 
65 (0.48 g, 1.69 mmol) and PEX (0.26 g, 1. 6  mmol). Were brought to reflux for 12 h and 
then concentrated under reduced pressure to afford light yellow oil. The oil was 
dissolved in Et2 0  and a white powder crashed out o f solution. The precipitate was 
isolated and then analyzed by 'H , 13C, and 31P NMR showing a mixture o f  2 diasteromers 
(0.057 g, 0.02 mmol, 13%). HRMS calcd for M +H+ o f C ,3H22N 0 3P 272.1415, found 
272.1456.
'H  NMR (CDCI3, 400 MHz): 8  7.58-7.34 (m, 5H), 4.69 (q, J =  6.4 Hz, 0.6 H), 4.32 (q, J  
= 6.4 Hz, 0.4 H), 3.60 (d, J =  11.0 Hz, 2.1 H), 3.41 (d, J =  11.9 Hz, 0.9 H), 2.76-2.51 (m,
1 H), 2.09-1.11 (m, 7 = 7 .1  Hz, 4 H), 1.82-1.79 ( m , J =  6.4 Hz, 3 H), 0.83 (t, .7=7.1 Hz,
0.9 H), 0.64 (t, 7 = 7 .1  Hz, 2.1 H).
13C N M R (C D C 13, 100 MHz): 5 138.3, 138.2, 130.3, 130.2, 130.0, 129.0, 128.8, 61.2, 
59.7, 57.8 (d, J P0Cm  = 9.2 Hz), 55.3 (d, JPCH = 149.5 Hz), 53.9 (d, JPCH = 147.3 Hz), 52.9 
(d, Jpocm  = 6.1 Hz), 32.0, 29.9, 22.2 (d, J =  9.2 Hz), 20.8 (d, J  = 9.2 Hz), 15.2, 14.3.
3 IPN M R (C D C 13, 171 MHz): 5 14.8, 14.6.
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[3-M ethyl-l-(l-phenyl-ethylam ino)-butyl]-phosphonothioic acid O-methyl ester (72).
Compound 59 (0.25 g, 0.78 mmol) and PEX (0.12 g, 0.74 mmol) were refluxed for 10 h 
and then transferred to a separatory funnel. Then 50 mL o f 0.2 M NaOH was added to 
the funnel followed by an extraction with CHCI3 (3 x 40 mL). After the CHCI3 
extraction, solid citric acid was added until the pH was about 5 and then CHChhsopropyl 
alcohol (4:1) was used to extract the product from the water layer. All organic layers 
from the CHChiisopropyl alcohol extractions were combined and dried over Na2S 0 4 
followed by concentration by reduced pressure to afford a light tan foam. The foam was
1 1 3  31isolated and then analyzed by H, C, and P N M R  showing a mixture o f 2 diasteromers 
(3:2), (0.041 g, 0.01 mmol, 18%). H R M S  calcd for M + H + o f C 14H 2 4 N O 2P S  302.1343, 
found 302.1389.
'H  NMR (CDCI3, 400 MHz): 5 7.57-7.32 (m, 5H), 4.71-4.51 (m, .7=7.1 Hz, 1 H), 3.72 
(d, .7=12.9 Hz, 1.2 H), 3.62 (d, 7  = 12.9 Hz, 1.8 H), 2.93-2.81 (m, 1 H), 1.88-1.83 (m, 7  
= 6.4 Hz, 3 H), 1.80-1.35 (m, 7 =  6.4 Hz, 3 H), 0.64 (d, 7 = 6 .4  Hz, 1.2 H), 0.55 (d ,7  =
6.4 Hz, 1.8 H), 0.37 (d, 7 =  6.4 Hz, 1.2 H), 0.21 (d ,7 = 6 .4  Hz, 1.8 H).
13C N M R (C D C13, 100 MHz): 5 137.7, 137.3, 130.6, 130.5, 130.4, 130.3, 129.6, 129.4, 
61.5, 61.0, 58.6 (d, J p c h  = 106.8 Hz), 58.0 (d, J p c h  ~ 103.8 Hz), 52.5 (d, J p o c h i  ~  6-1
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Hz), 52.1 (d, Jpocm  = 6.1 Hz), 39.3, 38.0, 32.8, 30.3, 25.9 (d, J =  9.2 Hz), 25.7 (d, J  
Hz), 23 .5 ,22 .9 ,22 .4 , 22.2.
31P NMR (CDC13, 171 MHz): 8  73.4, 72.9.
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ACE Assay
Phosphoramidon
lm L  o f HEPES shall be added to the bottle o f Phosphoramidon.
50pL shall be transferred into each of 20 Eppendorf tubes.
950pL o f le-4M  HEPES shall be added to each tube when needed. 
[Phosphoramidon] = 9.19963e-5M
FAGLA
277.8pL o f 95%EtOH shall be used to dissolve 25mg o f dipeptide.
40pL shall be transferred into each o f 5 Eppendorf tubes 
960pL o f le-4M  HEPES shall be added to each tube when needed.
[FAGLA] = 1.1747e-2M
Thermolysin
13.3067mL o f HEPES shall be used to dissolve 25mg o f protein in approximately 
2mL aliquots at a time.
The aliquots were then transferred to a small centrifuge tube.
lm L  o f suspension shall be transferred into each o f  13 Eppendorf tubes
lOOpL o f concentrate shall be diluted with 900pL o f le-4M  HEPES when
needed.
[Thermolysin] = 5.01 e-6 M 
APTA compounds
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W eigh approximately l-2m g o f compound and dissolve in 500pL of EtOH 
Calculate concentration and amount o f concentrate needed to produce lm L of 
9.19963e-5M compound.
[APTA’s] = 9.19963e-5M
500pL o f 2 .8279xl0‘3M FAGLA were diluted in 500pL o f 5 .01x l0 '5 M enzyme 
and 500pL o f pH 7.2, 1x1CT3M HEPES in a 96 well plate. The well plate was then 
incubated at 30 EC for 5 min in the well plate reader. The decrease in the absorbance o f 
FAGLA at L=345 was measured over a time o f 800 (later 180) seconds. A negative 
control o f 500pL o f FAGLA solution diluted in 1000pL o f HEPES was also performed to 
make sure that the decreasing o f A345 was due to the hydrolysis o f  FAGLA instead o f its 
natural decomposition. A second control o f 500pJL o f thermolysin in 1000pL o f HEPES 
was also performed to guarantee that the enzyme did not absorb at 345nm. Finally 500pL 
o f FAGLA were mixed with 500pL o f thermolysin and 500pL o f inhibitor, either the 
known inhibitor phosphoramidon, or an APTA compound.
These three solutions were then also analyzed on the Beckman UV-Visible 
spectrophotometer. The data was collected by Softmax pro and analyzed in Excel.
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